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Abstract
Cutaneous melanoma is the most aggressive and drug resistant form of skin cancer and is
responsible for most skin cancer related deaths in Australia and worldwide. Early detection of
the cancer is the single most import factor in the prevention of disease progression. Therefore
the identification and validation of highly sensitive and specific early stage diagnostic
biomarkers for melanoma has been of great interest in recent years. Elevated levels of
autoantibodies in the serum of early stage cancer patients have been associated with the
presence of cancer of the breast, lung, ovary, colon, head and neck and prostate. Therefore,
the presence of one or more serological autoantibody biomarkers in the blood of early stage
melanoma patients may assist with diagnosis of the disease and may be developed as a
routine diagnostic tool, such as a blood test, to aid the early detection of the cancer.
The aim of this project was to identify such diagnostic autoantibody biomarkers or panels of
these markers, displaying high frequency in patients but none or low frequency in healthy
volunteers, for the early detection of melanoma. The aim of the research was also to validate
the identified markers in a larger cohort and to establish the optimal single marker or panel of
biomarkers, displaying the highest sensitivity and specificity for melanoma.
To do this, we utilised serum samples from patients recently diagnosed with melanoma and
age and gender matched healthy volunteers, who were confirmed as melanoma, cancer and
autoimmune disease free. The samples were screened using a functional protein microarray,
developed by our collaborators Oxford Gene Technology, Oxford, UK. The array contains
1627 human recombinant proteins of various tumour origin.
Our results showed that eight of the proteins attached to the microarray surface, exhibited
high reactivity with melanoma patient sera and low or no reactivity with control sera and
were therefore considered potential diagnostic biomarkers for the early detection of
melanoma. Three of the microarray identified markers, namely SOX10, BRDG1 (STAP1)
and SCYL3, were chosen for further investigation to validate the results obtained from the
microarray in a larger cohort. We found that a combination of all autoantibody biomarkers
had the highest diagnostic potential for early stage melanoma patients relative to healthy
control samples. This finding coincides with recent studies which have found increased
diagnostic potential in various cancers when a panel of multiple autoantibody biomarkers is
utilised as opposed to individual markers alone. We also show here that two methodologies,
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the functional protein microarray and an in-house indirect ELISA, show similar sensitivity
and specificity scores for detection of melanoma autoantibodies in early stage melanoma
regardless of whether individual biomarkers or combinations of these markers are used. Thus
we confirm that these methods are appropriate for the identification and validation of
diagnostic autoantibody biomarkers for early diagnosis of melanoma.
Interestingly, in our cohort, female patients displayed significantly higher levels of
autoantibody markers than male patients. However, we found no statistically significant
differences in patient autoantibody levels with regard to disease stage or age.
In conclusion, our findings correspond with the hypothesis upon which this research was
based, that increased levels of autoantibodies in the serum of early stage melanoma patients
are indicative of a positive disease status and may therefore be utilised to diagnose melanoma
patients at an early stage.
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1. Introduction and Literature Review
Cutaneous melanoma (CM) is a highly treatment resistant, fatal skin cancer. It´s incidence
accounts for only 4% of all skin cancers, however, melanoma is responsible for 80% of all
recorded deaths from skin cancer (Lewis et al., 2005). Melanoma is the third most common
cancer in all age groups, and it is the most commonly diagnosed cancer in the 15-39 year age
group in Australia (Melanoma Institute Australia, 2013). It is also the leading cause of death
in young males within the 15-39 year age group (Threlfall and Thompson, 2010). Worldwide,
three million people are diagnosed with the cancer per annum (Kutting and Drexler, 2010).
Australia has the highest incidence of melanoma in the world with Queensland followed by
Western Australia being the states with the highest melanoma prevalence (Western Austalian
Cancer Registry, 2010). In order to better manage the disease and to increase survival rates,
there is a need for identification of diagnostic biomarkers for early stage disease, as late
diagnosis drastically reduces 5-year survival rates. By contrast, patients diagnosed with early
stage disease have a 5-year survival rate as high as 99% (Balch et al., 2009).
1.1 The origin of cutaneous melanoma
Melanoma is a malignant tumour of melanocytes, a subset of cells within the basal layer of
the epidermis of the skin. Melanocytes also occur in the bulb of the hair follicle (Fitzpatrick,
1971; Haaka and Scott, 2001; Nordlund and Boissy, 2001). Melanocytes originate from
neural crest cells and migrate to the basal layer of the epidermis during embryonic
development (Chin, 2003). Normally situated at the border between the dermal and the
epidermal layer of the skin (Figure 1), these cells are responsible for production of the
pigment melanin. This pigment is responsible for the variety of human skin colour
phenotypes (Rees, 2004). Furthermore, melanin pigment contributes to the natural defences
of the human body, as it absorbs ultraviolet (UV) radiation from the sun (Hsu et al., 2002).
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Figure 1: Location of melanocytes within the lower part of the epidermis of the skin. (Image
from Masonic Cancer Centre, http://www.cancer.umn.edu)
Melanocytes prevent UV radiation damage to the DNA of the cells of the epidermis, by
connecting to the keratinocytes via dendritic connections, forming a keratinocyte-melanocyte
unit. Within each of these units, melanin pigment is transported from a singular melanocyte

Figure 2: Melanocyte cellular extensions and melanin distribution. (Image from Science
Photo Library, http://www.sciencephoto.com)
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to up to 36 keratinocytes within the epidermal layer of the skin (Figure 2) (Chin, 2003).
In response to UV exposure, melanocytes proliferate resulting in an increase in the ratio of
melanocytes to keratinocytes. This can result in the formation of a mole, or naevus (Patton et
al., 2005). Melanocytes within a naevus eventually cease proliferation and become quiescent
or senescent. However, melanocytes within a naevus may become activated due to mutations,
with the result that there is uncontrolled replication of these cells (Patton et al., 2005).
Although approximately 60% of melanomas arise from existing naevi, it should be noted that
they can also arise de novo (Weatherhead et al., 2006).
There are two important stages of tumour growth within the epidermis; initially, uncontrolled
proliferation of melanocytes results in radial, or superficial growth, whereas at later stages
melanoma cells undergo a vertical growth phase. Once the melanoma growth phase reaches
the vertical phase, melanoma cell growth is no longer under keratinocyte control, enabling
melanoma cells to invade the dermis and therefore the circulatory and lymphatic systems
(Postovit et al., 2007).
1.2 Major risk factors associated for cutaneous melanoma
UV radiation (UVA and UVB) has long been accepted as a major environmental cause of
skin cancers including cutaneous melanoma (Leiter and Garbe, 2008; Mackie, 2005).
Individuals who have a history of multiple incidents of severe sunburn during their lifetime
and especially during their childhood, are said to have an increased risk of developing
melanoma (Cho and Chang, 2010). Certain phenotypes such as paler skin, blue eyes, red hair
and a large number of moles or freckles also increase the risk of developing melanoma
(Duffy et al., 2007). The most common body sites to be diagnosed with melanoma are the
back/buttock (37%), upper arm (21%), face (12%), neck (7%), forearm (7%), and lower
leg/foot (7%) in males. In females, the most common body sites to be diagnosed with
melanoma are the upper arm (23.1%), back/buttock (21.1%), lower leg/foot (17.3%), face
(9.6%) and forearm (9.6%) (Youl et al., 2011).
The risk of developing melanoma is increased when eumelanin is decreased in individuals as
a result of a single nucleotide polymorphism within a gene known as melanocortin 1 receptor
(MC1R) (Rees, 2004). This leads to a decrease in the amount of melanin pigment being
transported from melanocytes towards the keratinocytes and therefore a decrease in
protection from UV radiation of the sun, creating a greater risk of developing DNA mutations
3

(Costin and Hearing, 2007). There is a decreased risk of malignant melanoma in populations
with darker skin shades such as Native Americans, Hispanics and Asians as well as Africans
(Czarnecki and Meehan, 2000). About 10% of all diagnosed melanomas are known to be
caused by germline mutations in cyclin-dependent kinase 4 (CDK4) on chromosome 12, or
the tumour suppressor gene, cyclin-dependent kinase inhibitor 2A (CDKN2A), on
chromosome 9p21, indicating that family history is another risk factor for melanoma
(Bataille, 2000; Chin, 2003; Nagore et al., 2000).
Familial melanoma is also caused by a polymorphism in MITF (Yokoyama et al., 2011), a
master regulatory gene of melanocyte differentiation, proliferation and survival. MITF plays
a role in cancer cell survival by increasing expression of BCL2, an anti-apoptotic gene
(Banerjee, 2002; McGill and Horstmann, 2002). A germline variant, the E318K allele, results
in an MITF protein with impaired sumoylation resulting in differentially regulated MITF
targets, including BCL2 (Yokoyama et al., 2011).
Severe infections such as erysipelas have the potential to modify the course of melanoma
significantly, in some cases leading to regression and potentially complete resolution of the
cancer (Grange et al., 2002). Krone et al. (2005) showed that immune surveillance for
melanoma is induced or enhanced by prior contact with pathogens such as those vaccinated
with the Bacille Calmette-Guèrin (BCG) vaccine.
Epidemiological studies have shown that a deficiency in vitamin D increases the risk of
cancers including melanoma (Chen et al., 2010; Field and Newton-Bishop, 2011; Gandini et
al., 2005). Vitamin D has an anti-proliferative and pro-apoptotic effect on cancer cells; once
bound to the vitamin D receptor, it will result in the transcription of genes which play a role
in inhibition of MAPK signalling, apoptosis induction and cell-cycle inhibition. Therefore,
people with vitamin D deficiency are at higher risk of developing melanoma (Krishnan et al.,
2003).
1.3 Types of melanoma
Wallace Clark and his colleagues were the first to histologically classify melanoma into three
different forms: superficial spreading, lentigo malignant and nodular (Clark Jr, 1967; Clark Jr
et al., 1969). Dr. Richard Reed added a forth type which is known as acral lentiginous
malignant melanoma (Reed, 1976).
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Surface Spreading
Melanoma

Nodular Melanoma

Lentigo Maligna
Melanoma

Acral Lentiginous
Melanoma

Figure 3: Types of melanoma (Image adapted from Hoek, 2006)
Superficial Spreading Melanoma (SSM) accounts for 50-70% of all melanomas with 75% of
all SSM‟s arising de novo in the epidermis. SSM lesions typically show a wide variety of
pigmentation and a pagetoid spread of cancerous melanoma cells within the epidermis
(Demitsu et al., 2000).
Nodular Melanoma (NM) accounts for 15-35% of all melanomas. This type of melanoma is
characterised by the absence of a radial growth phase but the lesion can be polypoid, nodular
or pedunculated (Kiene et al., 1995; Plotnick et al., 1990).
Lentigo Maligna Melanoma (LMM) accounts for 5-15% of all melanomas and usually occurs
on sun-exposed locations of the body such as the face and the skin of the upper body,
particularly in elderly patients (Cohen, 1995). LMM is an in situ melanoma known as
“Hutchinson Freckle”. Only 5% of all patients with a lentiga maligna lesion progress to
develop lentigo maligna melanoma. This process may take several years (McKenna et al.,
2006).
Acral Lentiginous Melanoma (ALM) accounts for 5-10% of all melanomas and represents the
most abundant melanoma type in people with dark skin colours or those of Japanese origin
(Chen et al., 1999).
1.4 Melanoma staging methods
Melanoma is staged clinically according to the American Joint Committee on Cancer (AJCC)
guidelines (Balch et al., 2009). These guidelines involve the classification of melanomas into
stages based on information with respect to the primary tumour thickness, mitotic rate, the
5

presence of ulceration in the primary tumour and the presence of metastasis to lymph nodes
or distant sites. This is known as TNM staging.
Please refer to Table 1 and Figure 4 below for further details on the clinical characteristics of
each TNM melanoma stage.
Table 1: TNM staging of melanoma. Adapted from (Balch et al., 2009)
Stage
0
IA
(local
disease)
IB
(local
disease)
IIA
(local
disease)
IIB
(local
disease)
IIC
(local
disease)

Description
Primary tumour in situ
Primary tumour equal to or less than 1mm thick without ulceration and
without evidence of metastasis
Primary tumour with a thickness of less than 1mm with ulceration but no
evidence of metastasis OR primary tumour between 1 and 2mm thickness but
no evidence of ulceration or metastasis
Primary tumour between 1 and 2mm thickness with ulceration but no
evidence of metastasis OR primary tumour with thickness between 2 and
4mm without ulceration and without evidence of metastasis
Primary tumour between 2 and 4mm thickness with ulceration but no
evidence of metastasis OR primary tumour with thickness greater than 4mm
without ulceration and without evidence of metastasis
Primary tumour greater than 4mm thick with ulceration but without evidence
of metastasis

III

Primary tumour of any thickness with metastasis to one or several regional
(locoregional lymph nodes but without evidence of distant metastasis
disease)
IV
(metastatic
disease)

Primary tumour of any thickness with distant metastasis to other sites of the
skin, subcutaneous tissue, lymph nodes, lungs and visceral organs

6

Figure 4: Melanoma stages (Image from melanoma.org.nz)
TNM stage IV melanoma patients may be further subdivided according to their levels of
serum lactate dehydrogenase. Serum lactate dehydrogenase levels increase considerably with
increasing tissue damage, thus providing a measure of prognosis in late stage patients
(Agaruala, 2009; Balch et al., 2009).
The Breslow index is utilised in TNM staging of melanoma to determine the microstage of
melanoma and indicates the measurement in millimetres of the vertical thickness (Table 2) of
Table 2: The Breslow system of tumour staging (Breslow, 1975)
Total thickness of tumour

Five year survival rate

0.00-0.76 mm

98-99%

0.76-1.49 mm

85%

1.50-2.49 mm

84%

4.00 mm

44%
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the primary tumour (Breslow, 1969; Breslow, 1975).

This measurement has a strong

predictive value in the prognosis of patients with non-metastatic melanomas.
The Clark system (Clark et al., 1975) of melanoma microstaging is most commonly used by
pathologists to grade a tumour according to depth of invasion of atypical cells or
inflammatory infiltrates in relation to cutaneous histologic structures. The Clark level
correlates prognosis to the anatomical level of local invasion (Table 3). Any primary
melanoma tumour with a Clark level greater than II is considered an invasive tumour.
Table 3: Clark system of tumour staging (Clark et al., 1975)
Clark classification
Level I

Anatomical level of local invasion
Lesion involves only the epidermis = in
situ melanoma

Five year survival rate
100-98%

Lesion invades the papillary dermis, but
Level II

does not reach the papillary-reticular

96-72%

dermis
Invasion fills and expands the papillary
Level III

dermis, but does not penetrate the

90-46%

reticular dermis
Lesion invades into the reticular dermis,
Level IV

but does not penetrate into the

67-31%

subcutaneous tissue
Level V

Invasion spreads through the reticular
dermis into the subcutaneous tissue

48-12%

1.5 Diagnosis and prognosis of cutaneous melanoma
Initially, suspicious moles are examined using the ABCDE rule which determines a mole to
be a potential melanoma if the mole is asymmetrical, has an irregular border, is coloured
unevenly, has a diameter greater than 6mm and changes occur over time, hence the mole is
evolving (Abbasi et al., 2004).
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Once a biopsy has been obtained, the collected tissue sample is analysed by cytological
analysis and immunohistochemistry, using markers such as Human Melanoma Black 45
(HMB45), S100 calcium binding protein B (S100B) and Protein melan-A (MLANA), also
known as melanoma antigen recognised by T-cells 1 (MART-1); to assess the presence of
cutaneous melanoma (Mocellin et al., 2008; Pflugfelder et al., 2013). In order to increase the
accuracy of these analytical tests, it is necessary to utilise a larger number of markers with a
high sensitivity and specificity. In cases where immunohistochemistry results are indecisive,
electron microscopy may be utilised (Lai et al., 1998). On occasion, there may be difficulty in
diagnosing melanoma as the phenotype and genetic makeup can resemble the cells of other
cancer types (Sheffield et al., 2002).
Patients with early stage melanoma (TNM stage I) have a high (up to 99%) 5-year survival
rate after surgical removal of the primary tumour (Balch et al., 2009). Melanomas at early
stages (TNM 0-IIC) that are treated with non-surgical therapies have a recurrence rate of up
to 30% within the first 5 years after treatment (Zalaudek et al., 2003).
A poor prognosis and therefore high mortality rates are associated with metastatic melanoma
stages III and IV (Ireland et al., 2011; Jack et al., 2006; Schatton et al., 2008). When distant
metastases occur in non-visceral sites such as subcutaneous tissue, distant lymph nodes or
other locations within the skin, the patient‟s 1-year survival rate may be as low as 54%.
However, if the metastasis occurs in visceral sites, the 1-year survival rate is usually less than
35% (Gershenwald et al., 2008). Stage IV melanoma patients have a median survival as low
as 7.5-8 months with a mortality rate of up to 80% (Mervic, 2012; Postovit et al., 2007).
The most accurate prognostic measures for melanoma to date are primary tumour thickness,
the mitotic rate of primary tumours, the number of lymph node metastases, as well as the
location of metastases, the nature of the lymph node metastases as either microscopic or
macroscopic and elevated serum lactate dehydrogenase (Balch et al., 2009; Balch et al.,
2010). Micrometastases are diagnosed via sentinel or elective lymphadenectomy, while
macrometastases, defined as clinically detectable nodal or systemic metastases, can be
defined by therapeutic lymphadenectomy or positron emission tomography (PET) scans
(Marsden et al., 2010).
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1.6 Melanoma tumour progression and metastasis
Studies have shown that metastasis of the primary melanoma tumour arises in up to 15% of
melanoma patients with no evidence of melanoma tumour cells in their lymph nodes at the
time of primary surgery (Balch et al., 2009). This indicates that melanoma cancer cells have
the ability to spread not only via the lymphatic system but also throughout the circulatory
system where they are then called circulating melanoma cells (Reid et al., 2013; Weight et
al., 2006). The shedding of melanoma cells from the primary tumour and their invasion of the
bloodstream is a prerequisite of melanoma metastasis (Figure 4) (Koyanagi et al., 2005;
Mocellin et al., 2006). In fact, studies have shown that tumours shed millions of cells per day
into the blood stream, however, only a few cells establish metastases that are clinically
detectable (Figure 5) (Fidler et al., 2002; Jacob et al., 2007; Mitropapas et al., 2006; Palmieri
et al., 2007; Reid et al., 2013).

Figure 5: A diagram of the process of metastasis. (Figure adapted from Vereecken et al.,
2011)
For secondary metastases to be formed, metastatic melanoma cells need to undergo the
process of delamination, migration through tissues followed by cell adhesion at secondary
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sites. An inverse correlation between circulating tumour cells and overall patient survival has
been established for uveal melanoma (Ulmer et al., 2004) and other cancers such as
metastatic breast cancer (Cristofanilli et al., 2004). Understanding the biology and the
mechanism of metastasis provides new molecular targets and may help us to discover new
biomarkers.
Since circulating melanoma cells are present in the blood of patients with melanoma stages IIV (Freeman et al., 2012; Reid et al., 2013), detecting the presence of circulating tumour cells
in peripheral blood of patients or the presence of specific serological autoantibody
biomarkers against circulating melanoma cells or the primary tumour, can be used to
diagnose the disease in early stage melanoma patients (Freeman et al., 2012; Hoon et al.,
2000; Reid et al., 2013).
Primary tumour

Secondary tumour

Figure 6: Diagram of tumour cell metastasis (Image adapted from Pantel et al., 1999).
1.7 Treatment options available for cutaneous melanoma
For primary or secondary metastatic tumours, surgical excision is the optimal treatment (Tan,
2010). For stage IV inoperable melanoma, a wide range of treatment options such as
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immunotherapy, chemotherapy, interferon therapy or radiotherapy can also be considered;
however, the use of these treatments has drastically decreased in recent times, as more
specific treatments have been developed. To date, immunotherapies with interleukin-2 as
well as interferon therapy with interferon-alpha have proven to be successful in some cases
where metastasis is extensive. However, success rates are less than 10% (Steen et al., 2008).
Prior to 2011, the only chemotherapeutic agent approved for treatment of metastatic
melanoma was the intravenous drug dacarbazine (Blesa, 2009). Specific targeted therapies
for the treatment of late stage metastatic melanoma are now in clinical use to inhibit
melanoma growth. BRAF inhibitors specifically target the V600E mutation which is found in
greater than 50% of all melanomas. The mutation in BRAF results in activation of the
mitogen-activated protein kinase (MAPK) pathway (Davies et al., 2002), responsible for cell
regulatory processes including uncontrolled cell proliferation, increased motility,
angiogenesis as well as abnormal prolonged cell survival (Tuveson et al., 2003). Treatment
with these targeted therapies is successful in 78% of patients with dramatic reduction in
tumour size (Bhatia et al., 2009; Laurent-Puig et al., 2009). However BRAF inhibitors may
cause adverse side effects (Shepherd et al., 2010) and patients relapse after, on average, 7
months due to drug resistance (Solit and Rosen, 2011).
In 2011, a new drug, Ipilimumab, was approved by the US Food and Drug Administration.
This drug can stimulate T-cells to enhance the immunological response towards cancer cells
and increases patient survival rates from 6.4 months to 10 months (Wolchok et al., 2010b).
However, this drug only has a response rate in 11% of patients and it can cause serious
immune-related adverse events (Hodi et al., 2010; Wolchok et al., 2010a).
1.8 Biomarkers for early detection of cutaneous melanoma
There are two types of biomarkers: diagnostic biomarkers, which are used for screening tests,
and prognostic biomarkers, which are used once the disease has been confirmed through
diagnosis and which are used to predict a patient´s long term survival rates. Molecular tools
such as DNA, proteins, peptides or mRNA can be measured in tumour tissue with specific
qualitative and quantitative tools, and can be included as tumour biomarkers.
The research discussed in this document focuses on melanoma biomarkers found in the blood
serum of melanoma patients. These biomarkers are referred to as serological biomarkers.
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Serological biomarkers for cutaneous melanoma can be produced as part of an immunologic
response towards the primary tumour and secreted into the bloodstream.
To date, serological biomarkers are generally not utilised to diagnose melanoma, but may
prove valuable, particularly in occult melanoma cases where the primary tumour is not found
(Kamposioras et al., 2011). Moreover, following the surgical excision of their primary
tumour, melanoma patients generally do not receive further treatment and PET/ CT scans are
currently the only way to monitor a limited number of patients with suspected advanced
melanoma (Marsden et al., 2010).
In contrast to melanoma, prostate and ovarian cancers are commonly diagnosed using
serological antigen tests. Prostate cancer screening tests, for example, are based on a single
biomarker known as prostate specific antigen (PSA). PSA is produced in the prostate gland
and may leak into the patient‟s blood stream (Pan and McCahy, 2011). However, although
PSA serum levels are still used today, it has a specificity of less than fifty percent which
results in frequent false positive results and therefore several unnecessary radiotherapy and
surgical procedures (Zeliadt et al., 2011). Increased PSA serum levels may also arise due to
non-cancerous conditions such as enlargement of the prostate, prostatitis and urinary tract
infection (Pan and McCahy, 2011). In Australia, the College of General Practitioners does not
recommend population screening using PSA (The Royal Australasian College of General
Practitioners, 2009), whilst the Urological Society of Australia and New Zealand (USANZ)
recommend access to the test as it helps in diagnosing many patients correctly and therefore
increases patient survival rates. However, other test options such as a rectal examination may
also aid in the diagnosis of the cancer (Urological Society of Australia and New Zealand,
2009).
There have been attempts to discover highly specific serological melanoma biomarkers,
including LDH; however, their limitations do not support their clinical use as melanoma
biomarkers for early stage melanoma. Therefore, the search for serological biomarkers is
ongoing and more crucial than ever before, due to the increasing incidence of melanoma
worldwide (Ferlay et al., 2004).
1.9 Serological biomarkers for melanoma
To date, researchers have predominately focused on investigating increased levels of various
novel melanoma molecules in the blood to serve as potential biomarkers for the disease, but
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have so far failed to identify a single biomarker or a combination of biomarkers with
sufficiently high specificity and sensitivity for this cancer (Vereecken et al., 2011). Several
molecules currently utilised, or currently under investigation as potential diagnostic or
prognostic biomarkers for melanoma, include: c-reactive protein (CRP), S100-ß protein
(S100B), melanoma inhibitory activity (MIA), growth and angiogenesis factors such as
vascular endothelial growth factor (VEGF), galectin-3 (Gal-3), melanoma-associated
antigens, CD44, intercellular adhesion molecule 1 (ICAM-1), melanin-related metabolites,
matrix metalloproteinases (MMPs), cytokines, chemokines and their receptors and integrins,
lactate dehydrogenase (LDH), as well as circulating melanoma cells (Pflugfelder et al.,
2013).
The LDH enzyme has been considered the most appropriate prognostic serological marker of
metastatic melanoma and is used in the American Joint Committee on Cancer (AJCC) staging
system (Balch et al., 2009). As previously mentioned, elevated levels of LDH in serum of late
stage melanoma patients are used to determine the level of metastatic load as its levels
considerably increase with increasing tissue damage (Agaruala, 2009; Balch et al., 2010;
Balch et al., 2001b). However, this enzyme is not specific for melanoma, nor is it suitable for
disease diagnosis of early stage melanoma. Moreover, haemolysis and other factors in
patients with hepatitis often result in false positive results (Agaruala, 2009; Balch et al.,
2001a).
Molecules such as S100B are used during immunohistochemical analysis of excised
melanoma tumour tissue but this marker is not specific for early stage melanoma when
monitored in patient blood (Salama et al., 2008). To date, scientists have failed to show that
these molecules have the appropriate specificity and sensitivity to serve as diagnostic tools
for melanoma alone and the search for specific serological diagnostic melanoma biomarkers
is ongoing.
1.10 Immunologic response to cancer
Although the exact mechanisms involved are still unknown, the immune system has evolved
to achieve immune homeostasis in tissues through the delicate balance between pathogenic Tcell responses directed against tissue-specific antigens and the ability to inhibit these immune
responses, avoiding the development of autoimmunity by discriminating autologous from
non-autologous proteins (Rosenblum et al., 2011).
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In response to foreign, infectious agents, the immune system mounts an immune response via
a combination of adaptive and innate components. Initially, the detection of pathogenassociated molecular patterns (PAMPs) is sensed through either soluble patterns (PRRs) or
cell-borne proteins, found on dendritic cells, macrophages and other immunologic cells and
detected as non-autologous, initiating a strong immune response (Delves et al., 2011).
Following their maturation and migration towards to the lymph nodes, self-antigen peptideMHC complexes on antigen-presenting dendritic cells are recognised by T-cells (Rudensky et
al., 2006). Upon the expression of a self-antigen, the thymus-derived regulatory T-cells, also
known as Treg cells, become activated, proliferate and differentiate into a more potent type of
suppressor cells. These activated T-cells have been shown to mediate the resolution of organspecific autoimmune responses in mice (Rosenblum et al., 2011). Once differentiated, these
effector cells coordinate further macrophage activation, cytotoxic cell destruction and B-cell
responses, resulting in the simultaneous activation of the innate and adaptive immune system
to defend the body against foreign agents (Delves et al., 2011). Following the initial
inflammatory response, Treg cells have recently been found to be maintained within the
affected tissue as „regulatory memory‟ cells which are primed cells responsible for the
attenuation of subsequent autoimmune reactions (Rosenblum et al., 2011). Occasionally
however, these regulatory mechanisms are evaded and the autoimmune response is
maintained (Delves et al., 2011; Martini and Nath, 2009).
Immunologic responses towards cancers, including melanoma, are usually modest due to the
tumour cell‟s ability to recruit macrophages as well as other cells of the innate immune
system to mask the tumour cell as autologous or “self”, therefore supporting tumour survival
and growth. Furthermore, tumour cells commonly lack PAMPs and contain very few other
non-autologous determinants, resulting in tissue-resident dendritic cells remaining as
immature cells which fail to migrate to the lymph nodes to present antigen in response to
PAMP activation. This ultimately results in the failure of cells of the adaptive system to
migrate into tissues which are most commonly occupied by tumour cells, further ensuring
tumour survival (Rudensky et al., 2006). Inflammatory responses further enhance tumour
growth due to the release of inflammatory mediators such as cytokines and chemokines by
the tumour itself. These are able to recruit neutrophils and macrophages, as previously
mentioned, which in turn produce more cytokines and other inflammatory mediators,
promoting proliferation of the tumour as well as angiogenesis to provide a rich supply of
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oxygen and nutrients and waste disposal required by rapidly proliferating tumour (Frank et
al., 2011; Hammam et al., 2013).
Although the pathways involved in the production of autoantibodies and the immunologic
recognition of non-autologous antigens are still elusive, research on prostate cancer has found
an association between increased autoantibody levels in serum and prostate cancer
development (McAndrew et al., 2012; Wang et al., 2005). This research utilised microarray
technology to identify bromodomain-containing protein 2 (BRD2), eukaryotic translation
initiation factor 4 gamma 1 (eIF4G1), ribosomal protein L22 (RPL22), ribosomal protein LBa
(RPL13a), and hypothetical protein XP_373908 as the antigens most frequently bound to
autoantibodies in prostate cancer patient serum. Except for hypothetical protein XP_373908,
these structures were derived from intracellular proteins involved in regulating either
transcription or translation and resembled autologous proteins in patients. However, their
DNA sequences were not identical to the autologous proteins, which was suspected to have
stimulated autoantibody production (Wang et al., 2005). The autoantibody signature was
detected in only 5 of 14 serum samples from patients who had undergone prostatectomy and
in 3 of 11 serum samples from patients with hormone-refractory disease, suggesting that the
autoantibody profile is attenuated on removal of the "immunogen" or after treatment with
antiandrogens, chemotherapeutic agents, or both (Wang et al., 2005).
Furthermore, small-cell lung cancer research has shown that a number of rare paraneoplastic
neurologic autoimmune diseases (PNS) that damage neuronal tissues in a site remote from
the tumour but are unrelated to metastasis (Schiller and Jones, 1993), are strongly associated
with the cancer. Most patients harboured high levels of autoantibodies against neuronal
proteins which are abnormally expressed in small-cell lung cancer tumours (Diesinger et al.,
2002; Kazarian and Laird-Offringa, 2011). Interestingly, these autoantibodies can be found in
a large number of small-cell lung cancer patients without symptoms of neurologic damage as
well as some healthy volunteers, however in these cases the levels of the autoantibodies are
very low, suggesting that high levels of the autoantibodies may have value for the diagnosis
of small-cell lung cancer patients with PNS (Kazarian and Laird-Offringa, 2011). Currently,
there are at least 20 identified small-cell lung cancer-PNS associated autoantibodies and their
use in diagnostic tools may greatly assist in early detection as the neurological disease often
precede the small-cell lung cancer tumour development (Kazarian and Laird-Offringa, 2011).
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Additionally, a recent study has identified novel T-cell modulatory functions of the ATBbinding cassette sub-family B member 5 positive (ABCB5+) melanoma subpopulations
(Schatton et al., 2010). Blockage of ABCB5, an energy-dependent drug efflux p-glycoprotein
pump situated in the cell membrane (Frank et al., 2003), results in increased intracellular drug
accumulation which increases cytotoxicity, thereby improving melanoma chemotherapy
success (Frank et al., 2005). Tumorigenic ABCB5+ malignant melanoma initiating cells have
been shown to possess the ability to inhibit interleukin 2 (IL-2)-dependent T-cell activation
and to support the induction of CD4+CD25+FoxP3+ regulatory Treg cells, resulting in the
suppression of the immune response. ABCB5+ melanoma initiating cells have also been
shown to have lower expression levels of the melanoma-associated antigens ML-IAP,
MART-1, MAGE-A and NY-ESO-1, thereby evading an immunological response (Schatton
et al., 2010).
1.11 Improved disease diagnosis through autoantibody detection
Recent studies have shown an increase in autoantibody production in early stages of several
cancers (Gnjatic et al., 2009; Tan and Zhang, 2008) including cancer of the breast (Disis,
1994), lung (Diesinger et al., 2002), colon (Scanlan et al., 1998), ovary (Chatterjee, 2006)
prostate (Wang et al., 2005) and head and neck cancer (Carey, 1983).
Tumour cells have the capacity to produce immune modulatory signals (Pietras and Östman,
2010), exploiting and potentially escaping immune regulatory mechanisms (Bronte and
Mocellin, 2009; Kerkar and Restifo, 2012) to create an immune-suppressive and therefore
tumour-promoting microenvironment which is now regarded as an active instead of passive
participant in the survival and defence strategies of a tumour (Becker et al., 2013). Such a
tumour-promoting microenvironment is achieved by inducing central and peripheral
immunologic tolerance which is defined as “a state of unresponsiveness of the immune
system to substances or tissue that have the capacity to elicit an immune response” (Murphy,
2012). Central tolerance is induced in the thymus and bone marrow and represents one of the
main mechanisms that enable the immune system to discriminate autologous from nonautologous substances. Peripheral tolerance is induced in lymph nodes and other tissue and is
important for the prevention of over reactivity of the immune system to environmental
entities such as allergens. Central and peripheral tolerance of a tumour‟s microenvironment
such as in melanoma may be induced by promoting T-helper 2 (Th2) responses which are
regarded as rather tumour-promoting when compared to the Th1 responses, which are
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regarded as tumour-inhibiting (Becker et al., 2013). Furthermore, the expression of the homotetrametric heme-containing cytosolic enzyme tryptophan 2.3-dioxygenase (TDO) has an
inhibitory effect on anti-tumour immune responses, prolonging tumour survival (Pilotte et al.,
2012). The resulting central and peripheral tolerance leads to an increase in autoantibody
levels that would normally be removed by lymphocytes that have receptors that can bind
strongly to autoantibodies and remove these by induction of apoptosis of any autoreactive
cells or by induction of anergy of these cells (Murphy, 2012).
An alternate theory of the process of autoantibody production suggests that the precursors of
antibody producing cells, B lymphocytes, must integrate with two signals from two different
signal-detecting receptor proteins before antibody production and secretion into the
bloodstream is facilitated (Vinuesa and Goodnow, 2002). This mechanism is thought to be
the key for the immune system‟s ability to distinguish autologous from non-autologous
molecules and therefore greatly reduces autoantibody production (Bretscher and Cohn, 1970).
The theory suggests that any pathway, in which this two-signal control mechanism is
overcome, will result in the production of antibodies against the body‟s own proteins, hence
autoantibodies, and will therefore result in the presence of autoimmunity (Vinuesa and
Goodnow, 2002). The first signal of this control mechanism originates from the direct
binding of antigens to specific antigen receptors on cell-surface immunoglobulin molecules
with variable antigen-binding sites on B cells. The second signal commonly originates from
cytokine proteins as well as cell-surface growth factors produced by T helper cells, indicating
that the production of circulating antibodies depends on T helper cells and B cells. Only if the
B cells and T helper cells escape their tolerance to the same self-antigen simultaneously,
autoantibody production can occur.
For some important classes of microorganisms, however, the second signal can originate not
from T helper cells but from a specific component of the pathogen itself (Vinuesa and
Goodnow, 2002). Lipopolysaccharide is one such T-cell independent antigen and forms a
major part of gram-negative bacteria cell walls. The unique lipid group of the
lipopolysaccharide is recognised by the toll-like receptor 4 (TLR4) cell-surface receptor
present on all B cells (Poltorak, 1998). High concentrations of lipopolysaccharide stimulate
the proliferation of all B cells, however, at low concentrations, the simultaneous recognition
of the lipopolysaccharide by antigen receptors and TLR4 causes the production of a signal
which facilitates the production of circulating autoantibodies specifically by bacteria- specific
B cells (Cooke, 1994).
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The immune response towards tumour-associated antigens (TAAs) presented in early stages
of carcinogenesis, is thought to occur in response to cancer immunosurveillance, the process
by which the immune system recognises and destroys invading pathogens as well as host
cells that have become cancerous (Anderson and LaBaer, 2005; Caron et al., 2007; Finn,
2005). It has also been suggested that genetic, hormonal and environmental influences may
play a part in triggering autoimmunity.
Immunologic processes causing autoantibody production are believed to be generated by the
immune system in response to mutations, degradation, over-expression of proteins and/or the
release of proteins from damaged tissue, such as the increased release of VEGF at tumour
sites to enhance angiogenesis, or the release of cytokines and chemokines to cause
inflammation at the tumour site which further enhances tumour growth (Chen et al., 2005;
Järås and Anderson, 2011; Kazarian and Laird-Offringa, 2011; Scanlan et al., 2004).
Autoantibody production is also believed to be caused by mis-presentation or mis-folding of
proteins which may be recognised by the immune system leading to autoantibody production
and therefore, tumour-associated antigens (TAAs) or proteins that have undergone alternate
post-translational modifications (PTMs) may be recognised as non-autologous (Anderson and
LaBaer, 2005; Caron et al., 2007; Salazar and Disis, 2003), i.e. their phosphorylation,
glycosylation, oxidation or proteolytic cleavage could generate a neo-epitope or enhance selfepitope presentation and affinity to the major histocompatibility complex or T-cell receptor,
inducing an immune response (Hanash, 2003). A neo-epitope is an epitope which is located
within an unexposed region of the protein, preventing any interaction between the molecule
and antibodies or lymphocytes, therefore avoiding the induction of an immune response
against the molecule. The neo-epitope may only cause an immune response or tolerance when
it´s structure is exposed by a conformational change or stereochemical alteration of the
protein structure (Genovese et al., 2012).
The benefits of the diagnostic use of autoantibody production include improved disease
diagnosis in early stage cancer patients as the presence of autoantibodies may precede disease
symptoms (Tan and Zhang, 2008). Autoantibody detection may also offer high specificity
and sensitivity to improve accuracy of diagnostic tools as they are highly accessible, and are
easily obtained from the blood of patients so can be utilised for routine monitoring of
patients. Furthermore, unlike most other serological proteins in early stage patients,
autoantibodies are stable and easily purified from serum (McAndrew et al., 2012).
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1.12 Methodology of autoantibody detection
To advance the discovery of novel combinations of autoantibody biomarkers, techniques
which allow the simultaneous screening of multiple biomarkers are required. Examples of
such methodologies include serological analysis of tumour antigens by recombinant cDNA
expression cloning (SEREX), phage display, serological proteome analysis (SERPA),
multiple affinity protein profiling (MAPPing) or protein microarrays. For a comprehensive
overview and comparison of methodologies and associated processes used to detect multiple
autoantibodies simultaneously, please refer to (Zaenker and Ziman, 2013). A brief overview
of these methods will be provided here. Please also refer to Appendix 8.1 to view a summary
figure of methods commonly used to detect autoantibodies.
1.12.1 Serological analysis of tumour antigens by recombinant cDNA expression cloning
(SEREX)
SEREX, the serological analysis of tumour antigens by recombinant cDNA expression
cloning, was first developed in 1995 (Sahin et al., 1997; Sahin et al., 1995). This technique
utilises antibody reactivity with autologous cancer patient sera to identify immunogenic
tumour proteins (Caron et al., 2007; Gunawardana and Diamandis, 2007). The cDNA
expression library utilised in this methodology is constructed from tumour specimens of
interest and then cloned into λ-phage expression vectors which are used to transfect
Escherichia coli. The resulting recombinant proteins are then transferred onto a nitrocellulose
membrane which is incubated with diluted patient sera. Clones which are reactive with hightiter IgG antibodies are identified using an enzyme conjugated secondary antibody specific
for human IgG. The cDNA clone is sequenced and the autoantigen identified. The major
advantage of using SEREX is the fact that it allows the identification of tumour-associated
antigens from in vivo material. Another advantage of this technology is that it allows the
identification of several tumour-specific antigens in one experiment. Furthermore, both the
tumour-specific antigen and its coding cDNA are present in the same plaque when
immunoscreening is performed which allows the subsequent sequencing of matched cDNA
immediately. The disadvantage of SEREX is the high likelihood of false-positive results.
Secondly, the use of tumour tissue from a single cancer patient followed by screening with
autologous patient sera limits identification of tumour-associated antigens to that patient.
Moreover, this complex methodology does not detect alternate tumour-associated posttranslational modifications of antigens (Caron et al., 2007). Patients may also exhibit
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autoimmunity to autologous proteins and therefore irrelevant non-cancer-associated proteins
may be detected. Furthermore, parallel analysis with healthy donor sera as controls cannot be
performed easily.
1.12.2 Phage display
Alternatively, a cDNA phage display library is constructed directly from tumour tissue or a
cancer cell line derived from patient tumour material (Mintz et al., 2003). Phage clones which
bind to cancer sera are identified through a differential biopanning approach (Chatterjee et
al., 2009). Alternatively, a more cost-effective method is to construct the cDNA phage
display library by expressing the phage proteins fused to the antigens on the surface of
bacteriophages. The phage display method has the advantage of allowing the simultaneous
screening of a large number of antigens against the sera of cancer patients relative to serum of
healthy individuals (Mintz et al., 2003; Wang et al., 2005). The phage-display method has a
higher throughput value than the SEREX method but again, antigens with alternate posttranslational modifications cannot be detected using the phage-display method (Anderson and
LaBaer, 2005; Fossa et al., 2004).
1.12.3 Protein microarray
The protein array methods are advantageous in that they require only minute amounts of
patient sera (Robinson et al., 2003) while enabling the simultaneous screening of large
numbers of antigens in a single test (Balboni et al., 2006; Bouwman et al., 2003; Davies et
al., 2005; Kijanka and Murphy, 2009; Madoz-Gurpide et al., 2008; Sartain et al., 2006). In
this methodology, purified or recombinant as well as synthetic proteins are used.
Alternatively, fractured proteins of tumour origin are spotted onto the microarray platform.
Arrays are then incubated with patient and control sera (Anderson and LaBaer, 2005; Caron
et al., 2007; Madoz-Gurpide et al., 2001; Qiu et al., 2004). The array platform can be either
two dimensional (such as nitrocellulose membranes, microtitre plates or glass slides) or three
dimensional (such as nanoparticles or beads). While protein microarray methods are
commonly used to analyse recombinant proteins expressed from Escherichia coli cells, other
host expression systems such as yeast and insect cells have been used to produce libraries
presenting proteins with the correct post-translational modifications. The disadvantage
associated with this method is the requirement for high quality protein synthesis (Megliorino
et al., 2005). Furthermore, studies utilising protein microarrays are time restricted due to the
short shelf-life of protein arrays (Anderson and LaBaer, 2005; Ramachandran et al., 2004).
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1.12.4 Reverse-capture microarray
In this method, the antibodies reacting with specific proteins are spotted onto the microarray.
Similar to the protein microarray, the reverse-capture microarray is incubated with tumour
lysate and serum proteins and the microarrays with captured proteins are then further
incubated with sera from patients and controls. The autoantibodies are detected with
fluorescent-labelled secondary antibody (Ehrlich et al., 2006; Ehrlich et al., 2008; Qin et al.,
2006). The advantage of the utilisation of “reverse-capture” microarray technology is the
elimination of the need for recombinant proteins and allows the instant identification of
cancer-specific autoantibodies. However, only known antigens and their commercially
available antibodies can be analysed and immunoreactivity with post-translationally modified
antigens cannot be differentiated unless antibodies which bind exclusively to these antigens
are commercially available.
1.12.5 Serological proteome analysis (SERPA)
Serological proteome analysis (SERPA) (Klade et al., 2001) is also known as PROTEOMEX.
This technique is very useful for detection of tumour-associated antigens since it incorporates
an effective separation of a complex mixture of proteins based on their isoelectric points and
molecular weights through 2D electrophoresis and western blotting followed by identification
by mass spectrometry (Anderson and LaBaer, 2005; Chung et al., 2004; Nakanishi et al.,
2006). Proteins from the tumour tissue of interest are transferred onto a nitrocellulose
membrane and immobilised. The sera from cancer patients and controls are separately
screened using the immobilised proteins. The appropriate immunoreactive profiles are
compared and the cancer-associated antigenic spots are identified by mass spectrometry.
Similar to the SEREX technique, the advantage of the SERPA technique is the use of in vivo
derived tumour-associated antigens. Furthermore, the SERPA technique allows for the
identification of tumour-specific post-translational modifications and isoforms but is limited
in terms of the identification of low-abundance and transmembrane tumour-associated
antigens (Balboni et al., 2006; Canelle et al., 2005; Caron et al., 2007). SERPA also enables
the easy parallel analysis of tumour proteins with healthy donor sera as controls and avoids
the time-consuming construction of cDNA libraries, enabling this methodology to be
completed within a few hours compared to several days for SEREX and phage-display
technology. However, due to the way that western blots are prepared, SERPA can only be
used to detect linear epitopes (Casiano et al., 2006).
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1.12.6 Multiple affinity protein profiling (MAPPing)
The MAPPing methodology incorporates 2D immunoaffinity chromatography which is
followed by the identification of tumour-associated antigens by tandem mass spectrometry
analysis (Hardouin et al., 2007). In the first phase of the initial immunoaffinity
chromatography, lysate from cancer cell lines or tumour tissue containing nonspecific
tumour-associated antigens is bound to IgG that was obtained from healthy controls in an
immunoaffinity column. The flow-through fraction is then subjected to 2D immunoaffinity in
a column that contains IgG from cancer patients and columns can be utilised in parallel
(Caron et al., 2005). The tumour antigens which are captured in the patient columns are
eluted and digested for identification by nano-liquid chromatography mass spectrometry.
MAPPing ensures that the tumour antigens are maintained in a solution which allows the
potential identification of structural epitopes. The disadvantages associated with this method
include the restriction of the tumour antigen identification to antibody interactions with a low
dissociation rate constant. Furthermore, immunoprecipitation using these affinity columns
limits the detection of tumour antigens in more complex protein solutions, such as cell lysate.
1.13 Oxford Gene Technology functional protein microarray
The optimal technology, for multiplexing a vast number of antigens on one microarray, is the
Oxford Gene Technology (OGT) array. It requires minimal volumes of serum sample per
assay and hundreds of antigens can be analysed simultaneously. OGT functional protein array
is therefore an ideal platform for autoantibody biomarker discovery in early stage melanoma
patients, as the array enables the simultaneous assay of a large number of antigens due to its
ideal spotting density and requires as little as 5µl of undiluted serum sample to achieve this.
Importantly, to maintain the conformation of all epitopes of the spotted proteins and therefore
ensure highly specific autoantibody binding to these, the proteins are immobilised in their
natural, functional three-dimensional structure (Tan and Zhang, 2008). Production of
multiplex protein microarrays in other formats often results in denatured proteins when they
are immobilised on the glass slide of the microarray, thus non-specific binding may occur if
the proteins hydrophobic core is exposed and false negatives may result when the
discontinuous epitopes are destroyed. To avoid such situations, Oxford Gene Technology
attaches a unique biotin carboxyl carrier protein tag (BCCP) to each individual protein on the
functional protein array and attaches the proteins to the glass surface of the microarray via
biotinylation (Koopmann et al., 2005). As demonstrated in Figure 7, this special BCCP tag
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ensures that the correct three-dimensional functional protein structure and its epitopes and
hydrophobic core are maintained and it lifts the protein a certain distance away from the array
glass slide to ensure optimal binding (Butler et al., 1997; Houen and Koch, 1997; Yoshida et
al., 2004).
The OGT functional protein microarray utilised for this research consisted of a carefully
selected set of 1627 proteins, including kinases, signalling proteins, transcription factors and
secreted proteins. The proteins were chosen using the serological analysis of recombinant
cDNA expression libraries (SEREX). SEREX, as described in section 3.5.1, involves, in this
case, the use of diluted serum from cancer patients being used to screen for antibodies that
react against proteins expressed from cDNA libraries generated from cancer tissue. This
strategy of antigen selection is based upon the assumption that anti-tumour antibodies are
indicative of T- helper cells specific for such an antigen and therefore this method of protein
selection is highly specific for appropriate cancer related proteins, further ensuring the
accuracy of the microarray test (Stempfer et al., 2010).
The assay platform also allows the simultaneous testing of patient and control samples on one
microchip. The comparison of patient and control samples, processed under the same
conditions allows for exact comparison between the two groups.
To avoid technical error, every protein is applied to the microarray in quadruplicate. The
replicates of the proteins on the array therefore allow repeated measurement of autoantibody
binding.
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Figure 7: BCCP tag conserving the proteins natural three dimensional structure. (Image
adapted from McAndrew et al., 2012)

A previous study has successfully utilised the Oxford gene technology functional protein
microarray to identify autoantibodies (Wang et al., 2005). This study on prostate cancer, with
a cohort of 73 participants, identified 15 potential autoantibody biomarkers for prostate
cancer (McAndrew et al., 2012). A combination of these biomarkers showed both a
sensitivity and specificity of greater than 90% for prostate cancer. Out of this panel, 8 of the
15 potential prostate cancer autoantibody biomarkers had previously been associated with the
cancer, indicating the validity of this technology, and highlighted the ability of the array to
identify novel autoantibody biomarkers (McAndrew et al., 2012). By comparison, the single
biomarker PSA, currently utilised in prostate cancer screening has a sensitivity of 86% and a
specificity of 33% (Harvey et al., 2009). The findings of this prostate cancer OGT study are
currently being further substantiated in a larger cohort of 1800 participants (McAndrew et al.,
2012). We therefore hypothesised, that the OGT array could be utilised to similarly identify
autoantibodies specific for melanoma.
Other studies for the identification of highly sensitive and specific biomarkers or panels of
biomarkers for colorectal cancer and systemic lupus erythematosus (SLE), utilising the OGT
functional microarray platform, are awaiting publication (J. Poole-Johnson, OGT, personal
communication, May 2013).
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Traditional methods for the characterisation of autoantibodies such as enzyme-linked
immunosorbent assay (ELISA) are commonly used in laboratories to detect autoantibodies.
These however require large volumes of sample and substantial amounts of purified antigen.
This methodology can also be very time consuming. The sample volume may increase even
further when ELISA is used to profile for multiple antigens. Therefore, ELISAs are not
recommended for highly specific screening of hundreds or in some cases thousands of
antigens and the need for an improved assay methodology with equal or greater performance
than ELISAs such as the OGT microarray, is required. ELISAs are however, extremely useful
for confirming the presence of individual autoantibodies in serum, once identified by more
sensitive screening methods. We therefore hypothesised, that an indirect ELISA will aid in
the validation of the results obtained from the microarray in a larger cohort.
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2. Theoretical Framework
Melanoma continues to be an aggressive and drug resistant skin cancer (Lewis et al., 2005).
Late diagnosis of the primary tumour often results in invasive tumours in which melanoma
cells start to infiltrate the lymphatic and circulatory system resulting in metastasis and a
dramatic drop in the patient´s survival due to a lack of effective treatments. Once the
cancerous cells are detected by the patient‟s immune system, autoantibodies against the
cancer are thought to be produced due to differences in expression levels, mutations, protein
release from damaged tissue and mis-folding or mis-presentation of proteins. Levels of such
potential autoantibody biomarkers in the serum of early stage melanoma patients may be
utilised to diagnose melanoma and form the basis for a diagnostic blood test, as the levels of
autoantibodies may precede the occurrence of disease symptoms (Gnjatic et al., 2009).
High levels of autoantibodies have been associated with other cancers such as cancers of the
breast (Disis, 1994), lung (Diesinger et al., 2002), colon (Scanlan et al., 1998), ovary
(Chatterjee, 2006), head and neck (Carey, 1983) and prostate (Wang et al., 2005). Clinical
diagnosis of prostate cancer has traditionally utilised a single biomarker, prostate specific
antigen (PSA), (Zeliadt et al., 2011). However, this has a low sensitivity of 52% and a
specificity of up to 79% (Xie et al., 2011). More recent studies, utilising the OGT functional
protein microarray, have identified 15 potential autoantibody biomarkers for prostate cancer
and the use of combinations of these markers displayed greater sensitivity and specificity
than PSA alone (Harvey et al., 2009; McAndrew et al., 2012). Therefore in this study the aim
was to use OGT to identify highly specific and sensitive serological diagnostic autoantibody
biomarkers for the early diagnosis of cutaneous melanoma. Furthermore, this study aimed
also to validate identified biomarkers in a larger cohort.
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2.1 Hypothesis
Increased levels of autoantibodies in the serum of early stage (TNM 0 and I) melanoma
patients are indicative of a positive disease status and therefore may be utilised to assist with
diagnosis of melanoma patients at early disease stages.
2.2 Aims
Aim 1: To identify melanoma specific serological autoantibodies that can be used as
diagnostic biomarkers for early stage (TNM 0 and I) cutaneous melanoma.
To do this, serum from 40 participants, including 20 TNM stage 0 and I melanoma patients
and 20 age and gender matched healthy volunteers, was tested against 1627 antigens on an
OGT function protein microarray.
Aim 2: To confirm the expression of the potential autoantibody biomarkers by ELISA in a
larger population of melanoma patients.
This was achieved by testing the initial pilot study cohort as well as new samples against 3
identified biomarkers, namely SOX10, BRDG1 (STAP1) and SCYL3, using an indirect
enzyme-linked immunosorbent assay (n = 104, 113 and 114 respectively).
Aim 3: To statistically analyse the efficacy of single compared to combinations of melanoma
autoantibodies to act as diagnostic biomarkers.
This was achieved by utilising the statistical package SPSS Statistics 19 (IBM) to perform
parametric t-tests and one-way ANOVAs as well as nonparametric Mann-Whitney U and
Kruskal-Wallis tests, dependent on the nature of data distribution and normality, to determine
statistically significant differences between patient and control samples when tested against
any of the three autoantibody markers mentioned in Aim 2. Pearson chi-square test and
Fishers exact test were used to examine statistical significance of marker expression
incidence between patients and controls. Calculations of sensitivity, specificity and positive
and negative predictive value of individual markers versus marker combinations from the
microarray and enzyme-linked immunosorbent assays were performed for investigation of
diagnostic efficacy.
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3. Methods and Materials
3.1 Experimental design flow chart
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3.2 Participant recruitment
3.2.1 Pilot study cohort recruitment
Participants of the pilot study consisted of patients (n=20) recently diagnosed with melanoma
and age and gender matched healthy volunteers (n=20). Controls were confirmed as
melanoma, cancer and autoimmune disease free.
Healthy volunteers were recruited by the principal researcher through the display and
electronic circulation of a healthy volunteer recruitment flyer (appendix 8.2) which was
approved by the Human Research Ethics Committee of Edith Cowan University (No.8482).
Only early stage melanoma patients (TNM stage 0 and I) were recruited. Patients were
diagnosed as melanoma positive by pathological examination of excised lesions. All patients
were staged according to guidelines of the American Joint Committee on Cancer (AJCC)
(section 1.4). All patients were recruited by collaborating clinicians. All patient blood
samples were taken at the time of tumour excision. Patients at other melanoma stages were
not recruited to ensure that the small pilot study cohort represented, as closely as possible,
early stage melanoma.
All participants received an information letter, which was also approved by the Human
Research Ethics Committee of Edith Cowan University (No. 8482), outlining the parameters
of the study and all were required to sign a consent form to participate in the study (appendix
8.3). With consent from the participant, clinicians supplied patient clinical data to the
principal researcher. Patient samples were de-identified upon arrival at the research facility
and randomly assigned a study number. All personal details were kept confidential in a
locked facility and were not utilised for any other studies.
3.2.2 Complete study cohort recruitment
For confirmation of markers, a larger cohort was utilised. Participants of this complete/ final
research study cohort consisted of up to 60 patients of various disease stages recently
diagnosed with melanoma and up to 54 healthy volunteers, confirmed as melanoma, cancer
and autoimmune disease free. Healthy volunteers were recruited by the principal researcher
through the display and electronic circulation of a healthy volunteer recruitment flyer
(appendix 8.2) which was approved by the Human Research Ethics Committee of Edith
Cowan University (No.8482) and an appointment was arranged for the single blood sample
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collection to be performed by a trained phlebotomist in a phlebotomy approved room at the
research facility at Edith Cowan University.
For this cohort, patients of all melanoma cancer stages were recruited. Patients were
diagnosed as melanoma positive by pathological examination of excised lesions and staged
according to guidelines of the American Joint Committee on Cancer (AJCC) (section 1.4). As
described in section 3.2.1, with consent from the participant, clinicians supplied patient
clinical data to the principal researcher. Patient samples were de-identified upon arrival at the
research facility and randomly assigned a study number. All personal details were kept
confidential in a locked facility and were not and may not be utilised for any other purposes
or any other studies.
3.3 Sample collection
Once the participants provided consent to participate in the study, a single blood sample was
collected. For patients, the blood sample was collected at the time of tumour excision or
within 1 month of the initial diagnosis of melanoma.
A small volume of blood (8.5ml) was collected from patients and controls by a trained
phlebotomist at pathology centres or at Edith Cowan University by venous puncture into a
BD vacutainer serum separation tube (SST).
3.4 Serum extraction and storage
All blood samples were processed within 24 hours. Serum was extracted by centrifugation at
1600g for 10 minutes. Using a sterile micropipette, up to 10 aliquots of 100µl of serum were
pipetted into each of 10 UV-treated, sterile, 1.7ml microcentrifuge tubes. The
microcentrifuge tubes were labelled with the participants study number, the date of serum
extraction and the number of the aliquot and were then stored at -80°C until shipped for the
pilot study microarray experiment or until utilisation for the ELISA experiments.
3.5 Microarray technology – Pilot Study
Once sample collection of the pilot study cohort and serum extraction was complete for all
patients (n=20) and controls (n=20), two 100µl aliquots of each serum sample were sent to
Oxford University, Oxford, UK where the patented OGT functional protein microarray was
utilised to identify serological biomarkers highly expressed in patient samples but absent or
present in very low levels in healthy volunteer samples.
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3.5.1 Functional protein microarray construction
The protein microarray was constructed by Oxford Gene Technology (OGT) as follows:
Briefly, the SEREX mammalian gene collection database was used to identify tumour
associated factors. This was achieved by isolating mRNA from various cancer cells,
including melanoma, to construct a cDNA library which was then packaged into a
bacteriophage. The phages containing the cancer cDNA were then applied to a dish
containing an Escherichia coli (E. coli) lawn and the bacterial culture was infected with the
tumour cDNA under conditions that permitted expression of the tumour-derived proteins.
Replica “lifts” of the bacterial lawn were made using nitrocellulose membranes and these
were then probed with diluted antisera from various cancer patients. Bacterial colonies that
were expressing tumour-derived proteins were detected by antibodies within the patient
serum and could then be identified by isolating the phage from the relevant colony and
sequencing the tumour cDNA contained within the bacteriophage (Stempfer et al., 2010).
This method was used to obtain the 1627 proteins utilised on the microarray. A full list of
these genes/proteins is available upon request.
The full-length open reading frames of the identified 1627 target genes were cloned in-frame
together with a sequence which encoded the c-terminal E. coli biotin carboxyl carrier protein
(BCCP) fused to the myc epitope in a baculovirus transfer vector. The reading frame and
sequence were then sequence verified. The recombinant baculoviruses were generated,
amplified and expressed in Sf9 cells which were originally grown in suspension using
standard methods adapted for 24-well deep well plates (Chambers et al., 2004; Zhao et al.,
2003). Recombinant protein expression was analysed for protein integrity and biotinylation
by Western Blot and appropriate cells harbouring the recombinant proteins were lysed. The
lysates were spotted onto a streptavidin-coated glass slide (Schott Nexerterion, Jena,
Germany) in quadruplicate using a 300µm solid pin equipped QArray2 Microarrayer
processor (Genetix, New Milton, UK). This process was followed by a 2 hour incubation
period to allow the biotinylated proteins to bind to the straptavidin-coated glass surface. After
incubation, non-bound proteins were washed away and the slide was blocked with bovine
serum albimin (BSA). Following this step, the glass slide was referred to as a cancer antigen
array which was stored at -20°C where it is stable for a period of up to 12 months (Gnjatic et
al., 2009).
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Control proteins were also included on the microarray to ensure microarray quality control.
These included the BCCP tag, namely BCCP, BCCP-myc, β-galactosidase-BCCP-myc and βgalactosidase-BCCP, as well as Cy3/ Cy5-labeled biotinylated BSA marker, biotinylated IgG
and IgM dilution series, unlabeled biotinylated BSA and buffer only control spots (Gnjatic et
al., 2009).
3.5.2 Array profiling assay
Following the construction of the functional protein array, the serum samples collected for
this study were applied to the array followed by the addition of fluorescent labelled antihuman antibody IgG for detection. Wherever an antibody or autoantibody within the serum
sample interacted with its specific protein antigen, a plate reader detected fluorescence of the
bound fluorescently-labelled IgG within the appropriate microarray well. The location of
each protein on the microarray is known and therefore each protein bound by a specific
autoantibody could be identified. The intensity of fluorescence was proportional to the
amount of autoantibody-protein interaction (Gnjatic et al., 2009; McAndrew et al., 2012).
To achieve this result, the array was incubated in Quadriperm dishes (Greiner BioOne,
Stonehouse, UK) and placed on a horizontal shaker at 50 rpm for a period of 2 hours at room
temperature and individual sera samples were applied after being diluted 1:200 in 2ml buffer
(0.1% Triton X100 (v/v), 0.1% BSA (w/v) in PBS). After several washes, the anti-human IgG
was diluted 1:1000 in assay buffer and labelled with a fluorescent tag (Dako Cytomation) by
incubation for 2 hours at room temperature according to the manufacturer´s recommended
protocols. Following this, the plate was washed again and dried by centrifugation. The arrays
were scanned at 10µm resolution using a microarray scanner (Axon 4200AL with GenePix
Pro Software, Molecular Devices, Sunnyvale, CA 94089) and fluorescence of labelled IgG
was detected according to the manufacturer‟s instructions. Images taken were saved as 16-bit
tiff files and analysis was performed using GenePix software (Gnjatic et al., 2009). Local
background was subtracted automatically and the median fluorescence units (rfu) for each
microarray spot were recorded.
3.6 Statistical analysis of microarray results
For the statistical analysis of the microarray raw data, the median rfu values of the
quadruplicate spots for each of the 1627 proteins were averaged within each array, followed
by the proportional adjustment and normalisation of the average rfu values for all antigens
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according to the mean of IgG values obtained from all IgG controls and standard fluorescence
markers on the array. The adjusted values for each antigen were averaged across replicate
arrays and expressed as a percentage of interquartile differences per array (Gnjatic et al.,
2009). This was calculated through the application of the formula:
(Observed value) – (25th percentile) / (75th percentile) – (25th percentile)

All percentage values were then normalised using a standard quantile normalisation matrix
(Bolstad et al., 2003) in which all percentage values of each array are ranked and replaced by
the average of percentages for antigens with the same rank on all arrays. This resulted in data
distribution with identical median and quartile values, allowing interarray comparisons
(Gnjatic et al., 2009). Following the normalisation of the array data, the interquartile
difference was calculated for each antigen across all arrays, to establish a cut-off value to
enable the identification of autoantibodies showing significant seroreactivity. This was
achieved by calculating the average of all expression and fluorescence readings across the
microarray slide and defining every sample with a fold change of 2 or more above the
calculated average as a sample positive for the marker tested. In other words, for an
autoantibody to be defined as positive and therefore a potential serological biomarker for
early stage melanoma patients, the level of fluorescence of the particular autoantibodyprotein interaction needed to have values greater than 2-2.5 times the interquartile difference
above the 75th percentile (Gnjatic et al., 2009). All autoantibodies detected that applied to
these conditions were considered as a panel for further investigations.
Only application of serum to the OGT functional protein array and preliminary statistical
analysis of the microarray generated data were performed by OGT staff. The collection of
pathological and healthy sera and the remainder of the project and statistical analysis were
performed by myself, the MSc candidate.
In order to minimise the likelihood of false positive and negative results and to prove the
reliability of the serological biomarker, the marker must exhibit sufficient specificity and
sensitivity to melanoma tumours and should be absent or present in significantly lower
quantities in healthy volunteers. The specificity of such a biomarker is determined by the
proportion of healthy individuals that test negative for the marker, and the sensitivity of the
biomarker refers to the proportion of patients with confirmed disease testing positive for the
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marker (Vereecken et al., 2011). To test this, an ROC curve analysis was performed and the
area under the curve (AUC) was regarded as representation of sensitivity and specificity
scores. Two sample proportional statistical analysis and ROC curve analysis of sensitivity
and specificity of individual markers was performed utilising the statistical software
STATA® in order to establish if there was a significant relationship between the occurrence
of the selected specific autoantibodies and melanoma disease occurrence and therefore
diagnosis. Logistic regression analysis was not able to be performed due to “missing
observations” in tests with 100% success, such as where all test subjects or participants were
detected by a combination of markers or none of the participants were detected by a
biomarker panel. Furthermore, all data was checked for normal distribution by performing a
normalisation test in SPSS. For data with normal distribution, a t-test or one way ANOVA
was performed. Alternatively, a Mann-Whitney U test or Kruskal-Wallis test was performed
for data sets that did not exhibit normal distribution of data. Pearson chi-square test and
Fishers exact test were used to examine statistical significance of positive marker incidence
in the patient and control cohort.
3.7 Confirmation of microarray results using enzyme-linked immunosorbent assay
(ELISA)
To confirm these markers as effective diagnostic melanoma markers, 3 markers, namely
SOX10, BRDG1 (STAP1) and SCYL3, were chosen for further investigation. SOX10 and
BRDG1 (STAP1) were chosen as these markers displayed the highest frequency in patients
(30%) of those markers absent in the microarray control samples (Table 11). SCYL3 was
chosen for further study as it displayed the highest percentage difference of frequency in
patients versus controls in the microarray samples (45%) (Table 11).
As there were no commercially available ELISA kits for the three markers, an „in-house‟
indirect ELISA was constructed (Engvall and Perlman, 1971) as described in the following
sections. For the indirect ELISA, the appropriate antigen was bound to the well. Thereafter,
patient serum sample was applied to the well, resulting in the formation of an antigenantibody binding complex detected by a secondary HRP-labelled anti-human IgG antibody
(Figure 8).
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Figure 8: Indirect ELISA principle (Image from www.elisa-antibody.com)
3.7.1 SOX10 ELISA optimisation
To confirm that the indirect ELISA was an appropriate method to validate the microarray
pilot study results and to optimise sample and antigen concentrations, we chose SOX10 for
the majority of the optimisation tests as it was readily available commercially. For the first
SOX10 optimisation step, a set of four patient samples B2, B9, B11 and B16 and three
control samples CC1, CC2 and CC4 were chosen.
The indirect ELISA for this optimisation step was performed as follows: The required
number of U16 Maxisorp Nunc immune modules plate segments (Nunc, Thermo Scientific)
was assembled into the plate frame. SOX10 full-length human recombinant protein (Abvova)
was purchased at a concentration of 0.04µg/µl and diluted in 50mM carbonate buffer pH 9.6
to a final concentration of 0.5µg/ml, 1µg/ml and 2µg/ml respectively to assess the optimal
concentration for the final ELISA. 50µl per well of each of the solutions containing the three
protein coating concentrations were loaded into their appropriate well in the appropriate
columns (Figure 9). The plate was then covered with an adhesive film for microplates
(Sealplate) and the plate was left to incubate overnight on an orbital shaker at a speed of 150
rpm at 4°C.
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1 in 10000 dilution

1 in 100 dilution

1 in 5 dilution

neat sample

0.5ug/ul SOX10
1 in 10000 dilution

1 in 100 dilution

1 in 5 dilution

neat sample

1ug/ul SOX10
1 in 10000 dilution

1 in 100 dilution

1 in 5 dilution

2ug/ul SOX10

neat sample

Sample
B2
Patient
B9
serum
samples B11
B16
Control CC1
serum CC2
samples CC4
Blank

Figure 9: SOX10 optimisation ELISA 1 template
After 24 hours, the plate was washed 3 times with 300µl 1xPBS at pH 7.4 per well using a
plate washer (BioRad plate washer, model 1575) and 100µl of 3% PBS/ Bovine Serum
Albumin (BSA) („Bovostar‟ by BOVOGEN Biologicals) blocking solution was loaded into
each well. The plate was then covered again and left to incubate on an orbital shaker at 150
rpm at room temperature for 1 hour.
Following this incubation, plates were washed 3 times with 300µl 1xPBS per well and 50µl
of patient or control serum was loaded into the appropriate well (Figure 9). To assess the
optimal dilution of the serum sample applied to the assay, the samples were loaded onto the
plate in 4 different dilutions. The first column of each third of the 96-well ELISA plate was
coated with 50µl of neat or undiluted sera. The second column within each part of the ELISA
plate coated with a different protein coating concentration, had 50µl of 1 in 5 diluted sera
added to each well. The third column in each section of the ELISA plate was loaded with
50µl of 1 in 100 diluted sera per well and the fourth and final column contained the same
volume of sera per well but at a 1 in 10000 dilution. Blanks contained 50µl of 0.5%
PBS/BSA pH 7.4 buffer only (Figure 9). The plates were then resealed and left to incubate
for 2 hours on an orbital shaker at 4°C.
Following the sample incubation, plates were washed 3 times with 300µl 1x PBST (0.04%
tween at pH 7.4) per well and the rabbit anti-human secondary IgG antibody linked to
Horseradish Peroxidase (Thermo Scientific) was diluted 1 in 10000 by adding 5ul of
secondary antibody stock to 50ml PBST at pH 7.4. 50µl of this dilution was then added to
each well on the plate using a multichannel pipette. The plates were then resealed and
incubated for 1 hour on an orbital shaker at room temperature.
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The plate was re-washed with 300µl 1x PBST (0.04% tween at pH 7.4) per well. Thereafter,
50µl of a mixed solution of 6mL TMB Peroxidase Substrate and 6mL Peroxidase Substrate
Solution B (KPL Ltd.), at room temperature, was loaded into each well. The plate was then
covered with a light protective box and the assay was left to develop at room temperature for
approximately 30 minutes or until a dark blue colour was observed in each well indicating the
reaction of the TMP solution with Horseradish Peroxidise linked to the secondary antibody.
The reaction was stopped by adding 50µl of 1M H3PO4 phosphoric acid to each well and
plates were then read at A450 for chemiluminescence using the FLUOstar OPTIMA (BMG
Labtech) and results were analysed (section 3.8).
The next optimisation experiment was aimed at establishing the optimal sample dilution
factor. To test for this, six pilot study patients samples, B16, B2, B9, B11, B5 and B8, shown
to be positive for SOX10 in the microarray experiment (Appendix 3.5), were utilised. These
samples had a broad range of rfu values (high to low) in the microarray experiment. Five
control samples, 3 from the microarray experiment, shown to have no or low reactivity with
SOX10) and 2 new control samples were also included in this experiment.
This optimisation step followed the same indirect ELISA protocol described for optimisation
step 1, except that the entire 96-well plate was coated at the same antigen/protein coating
concentration of 1µg/ml, and serum was diluted 1 in 5, 1 in 10, 1 in 40 and 1 in 200 in 0.5%
PBS/BSA buffer and added onto the 96-well plate in duplicate (Table 4).
Other optimisation experiments, such as changes in development time and serum sample
Table 4: SOX10 optimisation ELISA 2 template
Patient sample number (SOX10
Control sample number
microarray fold-change)
Sample B16 B2
B9 B11 B5
B8
CC1 CC2 CC4 CC33 CC35 CC37
dilution (3.9) (3.5) (3.4) (2.4) (2.2) (2.0)
1 in 5
1 in 5
1 in 10
1 in 10
1 in 20
1 in 20
1 in 40
1 in 40
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concentration, were performed and their relevant results are discussed further in the following
sections.
3.7.2 BRDG1 (STAP1) and SCYL3 optimisation
The ELISA optimisation experiments performed for the remaining two markers BRDG1
(STAP1) and SCYL3 mirror the optimisation experiments described for SOX10 (section
3.7.1) STAP1 full-length human recombinant protein (Abvova) provided at a concentration
of 0.27µg/µl and SCYL3 full-length human recombinant protein (Abnova) provided at a
concentration of 0.1µg/µl were diluted in 50mM carbonate buffer pH 9.6 to a final
concentration of 0.5µg/ml, 1µg/ml and 2µg/ml respectively for the first optimisation step and
to 1µg/ml for any following optimisation step.
The results of these optimisation experiments for the BRDG1 and SCYL3 are described in
section 3.8.3 and 3.8.4.
3.8 ELISA optimisation results
As detailed above, optimisation experiments were performed to establish optimal antigen
coating concentration, patient serum sample dilution, dilution of secondary antibody and
development time for each of the three individual proteins tested.
3.8.1 SOX10 optimisation ELISA 1 results
For the first SOX10 optimisation step, a set of four patient samples, B2, B9, B11 and B16,
which displayed the highest fold change above the average rfu values for the marker SOX10
(Appendix 8.5) and three control samples were chosen. According to the microarray data,
none of the pilot study control samples tested positive for SOX10 (Appendix 8.5). Therefore,
the control samples CC1, CC2 and CC4, from the pilot study cohort tested on the microarray,
were randomly selected for utilisation in this optimisation step.
The following table over the page (Table 5) shows the results of SOX10 optimisation ELISA
trial 1 alongside the p-values for each sera dilution tested against the three coating protein
concentrations:
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Table 5: SOX10 ELISA optimisation trial 1 results
Dilutions
sample
number

neat

1in5

1in100

1in10000

neat

1in5

1in100

1in10000

neat

1in5

1in100

1in10000

B2

0.632

0.561

0.245

0.038

0.761

0.284

0.09

0.03

0.66

0.228

0.09

0.041

B9

1.265

0.938

0.249

0.035

1.513

1.243

0.245

0.027

1.518

1.181

0.284

0.04

B11

1.593

0.446

0.182

0.033

1.802

0.347

0.15

0.049

1.759

0.371

0.15

0.033

B16

1.878

1.402

0.215

0.037

1.956

1.269

0.17

0.027

2.071

1.135

0.136

0.046

CC1

1.584

0.448

0.138

0.025

1.622

0.352

0.114

0.032

1.46

0.38

0.104

0.028

CC2

0.853

0.312

0.096

0.039

0.789

0.268

0.087

0.027

0.779

0.25

0.078

0.036

CC4

1.876

0.365

0.148

0.037

1.972

0.274

0.107

0.037

1.895

0.242

0.114

0.037

Blank

0.042

0.031

0.04

0.039

0.044

0.033

0.037

0.03

0.036

0.044

0.048

0.035

2ug/ml protein concentration
p=
0.986

p=
0.059

p=
0.737

p=
0.035

1ug/ml protein concentration
p=
0.751

p=
0.000

p=
0.213

p=
0.252

p-value (patients versus controls)
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0.5ug/ml protein concentration
p=
0.935

p=
0.000

p=
0.166

p=
0.906

As seen in Table 5, a statistically significant difference between patient and control samples
can be observed at a coating protein concentration of 2µg/ml at a sample dilution of 1 in
10000. The next best conditions were the 1 in 5 serum sample dilution and 1 in 100 dilution
at protein concentrations 1µg/ml and 0.5 µg/ml. Nevertheless sample size may have great
effect on the p-value and increased sample sizes may prove other conditions to be optimal.
Neat samples did not display any statistical significance between patient and control samples
and were therefore not selected for further investigation. The 1 in 10000 dilution showed
significance between the two groups of samples at antigen plate coating concentration 2µg/ml
(p=0.035), however, the raw data values were too low and almost matched the value obtained
from the well containing the blank. Therefore, this dilution was also excluded from further
investigation. As illustrated in Table 5, the 1 in 5 dilution of sera showed significant
differences between patient and control samples under both the 1µg/ml and 0.5µg/ml antigen
coating conditions (p=0.000). It was therefore concluded that dilution factors equal to or
above 1 in 5 are optimal for utilisation in a SOX10 ELISA. Antigen coating concentration
1µg/ml was then chosen to be utilised in further SOX10 ELISA based experiments as it is the
concentration most consistent with similar studies (Desmetz et al., 2008; Gnjatic et al., 2009).
3.8.2 SOX10 optimisation ELISA 2 results
Table 6 demonstrates the results obtained from the second SOX10 optimisation trial which
was aimed at establishing the optimal sample dilution to be utilised in the final SOX10
ELISA. In this experiment, pilot study patient samples B16, B2, B9, B11, B5 and B8 were
tested for reactivity with the SOX10 antigen. The order, in which the samples are listed here,
mirrors the order in which the samples were added to the 96-well ELISA plate (table 4 and 6)
and also represents, in a descending order, their fold-change above the average rfu values on
the microarray. Control samples CC1, CC2, CC4 and CC33 were used in this optimisation
ELISA as these samples showed no or very low reactivity with the SOX10 antigen on the
microarray (Appendix 8.5). Additional control samples CC35 and CC37 were also included,
not previously tested on the microarray.
As indicated in Table 6, a statistically significant difference in reactivity between patient and
control samples was found at increasing higher dilutions. Lower dilution factors 1 in 5 and 1
in 10, did not display any significant difference between patients and controls. Therefore, a
dilution 1 in 200 was found to be optimal for the SOX10 ELISA as it showed the highest
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statistical significance between patient and control samples fluorescence readings. Samples
were also diluted 1 in 200 in the microarray experiment.
Additional optimisation experiments included the determination of the optimal SOX10 assay
development time. To ascertain this, the secondary antibody solution was applied to only one
of the duplicates and pH 7.4 PBST (0.4% tween) buffer only was applied to the other well.
The reaction was stopped and the time of assay development noted when the wells containing
the buffer only started to stain light blue, indicating background signal of the assay. For
SOX10, the optimal assay development time was established as 25 minutes, as this time
provided the lowest background signal versus the highest detection signal and a coefficient of
variation (CV) below 10% was regarded as an indication low interplate variability.
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Table 6: SOX10 optimisation ELISA 2 results

Patient sample number (SOX10 microarray foldchange)

Control sample number

Sample
dilution

B16
(3.9)

B2
(3.5)

B9
(3.4)

B11
(2.4)

B5
(2.2)

B8
(2.0)

CC1

CC2

CC4

CC33

CC35

CC37

1in5

1.053

0.424

0.901

0.474

0.270

0.797

0.413

0.246

0.309

1.260

0.324

0.338

1in5

1.050

0.421

0.926

0.453

0.237

0.710

0.380

0.240

0.326

1.375

0.313

0.337

1in10

0.681

0.393

0.852

0.392

0.220

0.701

0.296

0.197

0.270

0.466

0.280

0.304

1in10

0.529

0.359

0.506

0.355

0.224

0.671

0.295

0.200

0.280

0.725

0.297

0.304

1in40

0.353

0.243

0.514

0.293

0.158

0.466

0.213

0.145

0.190

0.201

0.200

0.192

1in40

0.328

0.252

0.360

0.318

0.187

0.532

0.218

0.174

0.217

0.218

0.239

0.107

1in200

0.404

0.215

0.287

0.695

0.116

0.097

0.174

0.219

0.186

0.115

0.158

0.174

1in200

0.368

0.225

0.297

0.655

0.121

0.102

0.176

0.117

0.196

0.112

0.165

0.163
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p-value
(patients
versus
controls)

0.200

0.078

0.035

0.028

3.8.3 BRDG1 (STAP1) optimisation ELISA results
Table 7 illustrates the results obtained from the BRDG1 (STAP1) optimisation experiment
which was aimed at establishing the optimal antigen coating concentration, sample dilution
and assay development time to be utilised in the final BRDG1 ELISA. In this experiment,
pilot study patient samples B17, B12, B7 and B22 were tested for reactivity with the BRDG1
(STAP1) antigen. These samples displayed the highest rfu fold change across the microarray
experiment for this marker (Appendix 8.5). Furthermore sample B17, which displayed the
highest fold-change on the microarray was added in duplicate to establish the optimal
development time for the BRDG1 (STAP1) assay. Since BRDG1 did not show any reactivity
with the control study cohort in the microarray experiment, the control samples CC20, CC23
and CC32 were randomly selected for inclusion in the experiment.
As displayed in Table 7, the optimal antigen coating concentration showing a statistically
significant difference between patients and control samples was 1µg/ml. Therefore, this
concentration was chosen to be utilised for further BRDG1 optimisation as well as for the
final ELISA. The optimal BRDG1 assay development time was timed to be 45 mins and the
optimal sera dilution was found to be 1 in 200.
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Table 7: BRDG1 (STAP1) optimisation ELISA 1 results
Dilutions
sample
number

1in5

1in50

1in100

1in200

1in5

1in50

1in100

1in200

1in5

1in50

1in100

1in200

B17
(without
sec. Ab.)

0.033

0.031

0.038

0.030

0.030

0.034

0.032

0.035

0.037

0.031

0.037

0.030

B17
(with
sec. Ab.)

0.565

0.206

0.120

0.102

0.502

0.118

0.118

0.098

0.451

0.162

0.116

0.065

B12

0.472

0.233

0.113

0.075

0.508

0.173

0.137

0.068

0.536

0.196

0.127

0.048

B7

1.371

0.145

0.073

0.062

0.317

0.120

0.123

0.057

0.311

0.122

0.296

0.053

B22

0.22

0.095

0.064

0.121

0.313

0.093

0.053

0.114

0.253

0.094

0.068

0.098

CC20

0.284

0.100

0.070

0.057

0.281

0.094

0.073

0.043

0.349

0.098

0.09

0.037

CC23

0.328

0.140

0.094

0.068

0.426

0.152

0.104

0.042

0.518

0.119

0.096

0.032

CC32

0.342

0.120

0.076

0.063

0.392

0.133

0.106

0.039

0.402

0.120

0.086

0.035

2ug/ul
0.099

0.057

0.010

1ug/ul
0.027

0.047

0.890

0.329

0.5ug/ul
0.008

p-value (patients versus controls)

45

0.229

0.062

0.087

0.121

3.8.4 SCYL3 optimisation ELISA results:
Table 8 illustrates the results obtained from the SCYL3 optimisation trial which was aimed at
establishing the optimal antigen coating concentration, sample dilution and assay
development time to be utilised in the final SCYL3 ELISA. In this experiment, pilot study
patient samples B6, B5, B19 and B10 were tested for reactivity with the SCYL3 antigen.
These samples displayed the highest rfu fold change across the microarray experiment for the
marker. Furthermore sample B6, which displayed the highest fold-change on the microarray
(Appendix 8.5) was added in duplicate to establish the optimal development time of the
SCYL3 assay. The control samples utilised in this experiment were CC6, CC14 and CC21.
These samples were tested against this marker on the microarray but did not show positivity
for the marker and should therefore show no or very low reactivity with the SCYL3 antigen
coated onto the well.
As displayed in Table 8, the optimal antigen coating concentrations showing a statistically
significant difference between patients and control samples were 1µg/ml and 0.5µg/ml. The
1µg/ml concentration was chosen to be utilised for further SCYL3 optimisation as well as for
the final ELISA. The optimal SCYL3 assay development time was 35 mins and further
optimisation ELISAs showed that a 1 in 200 dilution was also the optimal sample dilution.
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Table 8: SCYL3 optimisation ELISA trial 1 results
Dilutions
sample
number

1in50

1in100

1in200

1in400

1in50

1in100

1in200

1in400

1in50

1in100

1in200

1in400

0.026

0.024

0.044

0.027

0.027

0.036

0.036

0.044

0.027

0.029

0.034

0.034

0.367

0.237

0.145

0.087

0.228

0.163

0.099

0.079

0.175

0.14

0.092

0.067

B5

0.166

0.114

0.089

0.062

0.132

0.092

0.074

0.064

0.125

0.094

0.069

0.057

B19

0.185

0.116

0.087

0.074

0.151

0.117

0.080

0.083

0.141

0.093

0.080

0.067

B10

0.278

0.163

0.108

0.063

0.167

0.121

0.083

0.058

0.155

0.113

0.083

0.061

CC6

0.299

0.194

0.112

0.080

0.184

0.170

0.094

0.081

0.231

0.153

0.094

0.074

CC14

0.164

0.117

0.093

0.079

0.133

0.114

0.079

0.072

0.126

0.119

0.132

0.069

CC21

0.422

0.265

0.175

0.128

0.300

0.225

0.152

0.111

0.313

0.204

0.17

0.117

B6
(without
secondary
antibody)
B6 (with
secondary
antibody)

2ug/ml
0.751

0.791

0.333

1ug/ml
0.071

0.204

0.403

0.043

0.5ug/ml
0.265

p-value (patients versus controls)
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0.106

0.313

0.152

0.016

3.8.5 Final ELISA protocol
After optimisation of ELISAs for all three markers, SOX10, BRDG1 (STAP1) and SCYL3, a
final ELISA protocol was devised and is described below:
The required number of U16 Maxisorp Nunc immune modules plate segments (Nunc,
Thermo Scientific) was assembled into the plate frames. The full-length human recombinant
protein stock solution of each marker was diluted in 50mM pH 9.6 carbonate buffer to a final
concentration of 1µg/ml. 50µl per well of each of the protein coating buffer concentration
solutions were loaded into the 96-wells per plate. The plates were then covered with an
adhesive film for microplates (Sealplate) and the plates were left to incubate overnight on an
orbital shaker at a speed of 150 rpm at 4°C.
After 24 hours, the plates were washed 3 times with 300µl 1xPBS at pH 7.4 per well using a
plate washer (BioRad plate washer, model 1575) and 100µl of 3% PBS/ Bovine Serum
Albumin (BSA) („Bovostar‟ by BOVOGEN Biologicals) blocking solution was loaded into
each well. The plates were then covered again and left to incubate on an orbital shaker at 150
rpm at room temperature for 1 hour.
Following this incubation, plates were washed 3 times with 300µl 1xPBS per well and 50µl
of 1 in 200 diluted patient and control serum, diluted with 0.5% pH 7.4 PBS/BSA buffer, was
loaded into the appropriate well. A blank containing 50µl of 0.5% PBS/BSA pH 7.4 buffer
only was also added to each plate along with 5 standard points.
The standard solution for each marker was made by combining 100µl of each pilot study
patient sample that displayed positivity for SOX10, BRDG1 (STAP1) and SCYL3 (section
8.6) on the microarray. A serial 1 in 2 dilution was then performed with addition of the
diluent 0.5% pH 7.4 PBS/BSA buffer and the top 5 dilutions were added to each plate as a
standard curve. Results of the standard curve from each ELISA plate were used to calculate
interplate variability, as shown in the results section.
The plates were then resealed and left to incubate for 2 hours on an orbital shaker at 4°C.
Following the sample incubation, plates were washed with 300µl 1x PBST (0.04% tween at
pH 7.4) per well and the rabbit anti-human secondary IgG antibody linked to Horseradish
Peroxidase (Thermo Scientific) was diluted 1 in 10000 by adding 5ul of secondary antibody
stock to 50ml PBST at pH 7.4. 50µl of this dilution was then added to each well on the plate
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using a multichannel pipette. The plates were then resealed and incubated for 1 hour on an
orbital shaker at room temperature.
The plates were re-washed with 300µl 1x PBST (0.04% tween at pH 7.4) per well.
Thereafter, 50µl of a mixed solution of 6mL TMB Peroxidase Substrate and 6mL Peroxidase
Substrate Solution B (KPL Ltd.), at room temperature, was loaded into each well. The plates
were then covered with a light protective box and the assay was left to develop at room
temperature until a dark blue colour was observed; 25 minutes for SOX10, 45 minutes for
BRDG1 (STAP1) and for 35 minutes SCYL3.
The reaction was stopped by adding 50µl of 1M H3PO4 phosphoric acid to each well and
plates were then read for chemiluminescence at A450 using the FLUOstar OPTIMA (BMG
Labtech).
3.8.6 Statistical analysis of final ELISA results
Upon collection of enzyme-linked immunosorbent assay results, data was tested for normality
through utilisation of the „explore descriptive statistics‟ feature of the statistical package
SPSS Statistics 19 (IBM). Data was numerically tested for normalisation through application
of the Shapiro-Wilk test and significance greater than 0.05 was considered an indication of
normally distributed data. To test for statistically significant differences in rfu values between
patient and control samples, nonparametric Mann-Whitney U tests were performed using
SPSS where data was abnormally distributed. For data that was normally distributed, a t-test
was utilised. A nonparametric analysis was conducted if at least one groups displayed
abnormal distribution of data. When only one value was available to be utilised for such
comparisons, as in situations where only one sample represented a group ie.: only one control
sample showed positivity for a marker, the one-way ANOVA nonparametric alternative
Kruskal-Wallis test was performed instead of the Mann-Whitney U test or a one-way
ANOVA was performed for normally distributed data, as both the Mann-Whitney U and ttest require a minimum of two values or two samples per group. Pearson chi-square test and
Fishers exact test were used to examine statistical significance of positive marker incidence
in the patient and control cohort. Box-plot graphs were constructed for the majority of
comparative statistical analyses. The statistical package SPSS Statistics 19 (IBM) was further
utilised to search for significant differences in incidence between age groups, gender and
disease stages in patients positive for the markers. Due to the abnormal distribution of the
majority of the data obtained in this research study, a nonparametric Kruskal-Wallis test was
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performed to search for such differences between groups and any result displaying p<0.05
was defined as statistically significant. The sensitivity of a marker or combination of markers
was determined by the percentage of patients diagnosed as true positives for the marker or a
combination of markers. The specificity of a marker or combination of markers was denoted
as the percentage of healthy volunteers or controls being diagnosed as true negatives or
melanoma free and the positive and negative predictive values of a marker or combination of
markers was denoted as the proportions of positive and negative results of a marker or a
combination of markers. The term positive predictive value (PPV) is defined as the number
of true positives divided by the number of true positives plus the number of false positives.
Or in other words, the PPV equals the number of true positives divided by the total number of
positive tests. The term negative predictive value (NPV) is defined as the number of true
negatives divided by the number of true negatives plus the number of false negatives. Or in
other words, the NPV equals the number of true negatives divided by the total number of
negative tests (Fletcher and Suzanne, 2005). Finally the raw data results from both
methodologies, the microarray and ELISA experiments, were compared for statistical
significance between rfu values for the microarray and chemiluminescence values for the
ELISA, through utilisation of the Mann-Whitney U test.
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4. Results
4.1 Pilot study cohort
The pilot study cohort (n=40) consisted of twenty patients recently diagnosed with melanoma
and twenty age and gender matched healthy volunteers, confirmed as melanoma, cancer and
autoimmune disease free. Of the twenty patient samples, sixteen were male patients and four
were female patients. The number of male and female control samples matched those of the
patient cohort. Out of the twenty patient samples, five samples originated from patients with
TNM stage 1 melanoma of which three were male samples and two were female samples.
The remaining fifteen samples originated from TNM stage 0 in situ melanoma patients of
which thirteen were male samples and two were female samples. Below is a summary of the
average age of the pilot study participant with respect to their gender (Table 9). The age
difference investigated here represented normally distributed data and therefore an
independent t-test was utilised to calculate potential significant differences between the
average age of male and female patients and controls. In the pilot study cohort, there was no
significant difference in demographics between patients and controls (Table 9).
Table 9: Average ages in years of pilot study cohort with respect to gender

Male
Female

Patient (years)

Control (years)

p-value

58.31
56.25

55.88
54

0.926
0.973

A full list of patient clinical data including stage, primary tumour location, previous history
of melanoma and other diseases as well as blood sample collection time relative to disease
diagnosis is attached in Appendix section 8.4.
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4.2 Microarray results (OGT)

4
1627
recombinant
proteins on
microarray

8
potential diagnostic
Cutaneous
Melanoma
biomarkers

highest frequency in
patients samples vs.
frequency in control
samples
4
high frequency in patients
and absent in controls

Figure 10: Eight markers were identified by the microarray platform as potential CM
diagnostic biomarkers
Sera from all pilot study participants (n=40) were analysed on the Oxford Gene Technology
(OGT) functional protein microarray for expression of autoantibodies specific to melanoma.
Out of 1627 various human recombinant proteins attached to the functional protein
microarray, eight were identified as potential diagnostic cutaneous melanoma biomarkers due
to their reactivity with patient sera and low or no reactivity with control sera. Of these eight
markers, four had the highest frequency in patient versus control samples and the remaining
four displayed a high frequency in patient samples and were absent in control samples
(Figure 10).
Figure 11 below illustrates the rfu fold change values in each pilot study sample relative to
the 4 markers identified with the highest frequency in patient versus control samples. Any
sample displaying a fold-change greater than 2 (marked by a red line) was regarded as
positive for the marker tested.
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Figure 11: Pilot study sample rfu values for SCYL3, ENO2, NRBF2 and PAGE5

Figure 12: Pilot study rfu values for SOX10, STAP1, SSX7 and SPANXN1
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Figure 12 on the previous page illustrates the rfu fold change value in each pilot study sample
relative to the 4 markers that displayed a high frequency in patient samples and were absent
in control samples.
Table 10 summarises the results for all the identified markers. For each marker, the mean rfu
fold change (>2) in samples and controls above the overall background median rfu value for
the array is given.
For SCYL3 there was a statistically significant difference between microarray fluorescence
fold change values in patients versus control samples tested on the OGT microarray
(p=0.001). The markers STAP1 and SSX7 also displayed statistically significant differences
in patient and control fold change values (p=0.012 and p=0.033 respectively).
Table 10: Mean rfu fold change in patients and controls for each potential marker

Marker

rfu value in
patients (mean ±
Std Dev)

rfu value in
controls (mean ±
Std Dev)

Difference (pvalue*)

SCYL3

3.65± 1.84

2.22 ± 0.96

0.001

ENO2

2.85 ± 2.53

1.74 ± 0.80

0.098

NRBF2

2.87 ± 2.36

2.17 ± 2.28

0.126

PAGE5

1.96 ± 1.96

1.02 ± 0.56

0.292

SOX10

1.82 ± 0.84

1.35 ± 0.20

0.063

STAP1

2.49 ± 2.63

1.32 ± 0.19

0.012

SSX7

1.77 ± 0.82

1.34 ± 0.21

0.033

SPANXN1

1.45 ± 0.81

1.23 ± 0.24

0.543

*p-value obtained by Mann-Whitney U analysis; p<0.05 was regarded as significant
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Table 11 and figure 13 below summarise the frequency with which the eight biomarkers were
present in patient and control sera:
Table 11: Frequency of 8 microarray identified markers in patient versus control samples
Protein
Name

Frequency Frequency Difference Frequency Frequency Difference
in patients in controls
in patients in controls
(n = 20)
(n = 20)
(n)
(%)
(%)
(%)

SCYL3

17.0

8.0

9.0

85.0

40.0

45.0

ENO2

11.0

4.0

7.0

55.0

20.0

35.0

NRBF2

10.0

3.0

7.0

50.0

15.0

35.0

PAGE5

8.0

1.0

7.0

40.0

5.0

35.0

SOX10

6.0

0.0

6.0

30.0

0.0

30.0

STAP1

6.0

0.0

6.0

30.0

0.0

30.0

SSX7

5.0

0.0

5.0

25.0

0.0

25.0

SPANXN1

4.0

0.0

4.0

20.0

0.0

20.0

The autoantibody biomarkers with highest frequency in patient samples relative to their
frequency in control samples are displayed in the top four rows of Table 11, while the
autoantibody biomarkers identified with high frequency in patients but no positivity in
control sera are shown in the bottom four rows if table 11 (grey). SCYL3 exhibits the highest
percentage difference in frequency between patient and control sera (45%). Moreover, this
marker has a 10% higher frequency of positivity in the patient versus control sera relative to
markers ENO2, NRBF2 and PAGE5 which exhibit 35% difference in frequency between
patients and controls. The difference in frequency of positivity between patient and control
sera was 30% for SOX10 and BRDG1 and 25% and 20% respectively for SSX7 and
SPANX1.
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Figure 13: Frequency of the 8 biomarkers in patients versus controls
Figure 13 provides graphical representation of the ability of the potential biomarkers to
identify melanoma autoantibodies in patient versus control samples. SCYL3 diagnosed 85%
of the patient cohort as melanoma autoantibodies, while ENO2, NRBF2 and PAGE5 were
positive in 55%, 50% and 40% of patients respectively. SOX10 and STAP1, SSX7 and
SPANXN1 were positive in 30%, 25% and 20% of the patients respectively; however,
according to these preliminary results, their specificity when utilised in a clinical setting
would be as high as 100% since none of the control samples showed positivity for any of
these 4 markers. PAGE5 incorrectly diagnosed one control sample as melanoma positive and
diagnosed 40% of patient samples correctly. However, this resulted in a frequency difference
between patient and control samples of 35%.
For cross-referencing purposes, section 8.5 in the appendix contains tables that illustrate the
samples positive for the 8 potential biomarkers identified on the OGT microarray. The
sample number, participant age, gender and rfu fold change for the appropriate marker are
provided in this section as are the mean and range for each marker. Samples that did not
display positivity for the markers were not included in the tables; however, all pilot study
cohort samples and the relative sample rfu fold-change values were included in all of the
following statistical analysis.
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4.2.1 Marker expression relative to stage, gender and age
Table 12: Mean rfu fold changes for each marker relative to disease stage

Marker

stage 0 rfu fold
change (mean ± Std
Dev)

stage I rfu fold
change (mean ± Std
Dev)

Difference (pvalue*)

SCYL3

3.93 ± 2.00

2.82 ± 0.92

0.275

ENO2

3.14 ± 2.83

1.98 ± 0.97

0.569

NRBF2

2.80 ± 2.48

3.06 ± 2.22

0.827

PAGE5

2.17 ± 2.20

1.34 ± 0.84

0.693

SOX10

1.73 ± 0.76

2.10 ± 1.10

0.311

STAP1

2.66 ± 3.02

1.98 ± 0.72

0.484

SSX7

1.83 ± 0.91

1.60 ± 0.52

0.790

SPANXN1

1.57 ± 0.90

1.06 ± 0.15

0.175

*p-value obtained by Mann-Whitney U analysis; p<0.05 was regarded as significant

Table 12 shows that there were no statistically significant differences between stage 0 and I
patient microarray fluorescence fold change values. Interestingly, mean rfu fold change
values were generally higher in stage 0 patients than in stage I (75%) patients, except for
markers NRBF2 and SOX10 where stage I melanoma patients displayed higher rfu fold
change values than stage 0 melanoma patients.
Pearson chi-square test and Fishers exact test were used to examine statistical significance of
microarray marker expression in patients relative to melanoma TNM stage, gender and age
(Table 13). The microarray patient cohort contained patients of early disease TNM stage 0
and I only. Initially, the cohort was divided into three age-groups, namely 18-34 years, 35-64
years and 65 years and above, which had been utilised to compare patient marker expression
relative to age in the final ELISA experiments (section 4.4.3). However, the data from age
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groups 18-34 years and 35-64 years were pooled as there was only one representative sample
of the 18-34 year age group in the microarray cohort. The pooling of small sample size
groups was regarded a standard method to avoid small sample size comparisons (Dawson and
Trapp, 2001). Incidence percentages for each category, disease stage, gender and age, are
summarised in Table 13. There was no significant difference in incidence in the pilot study
patient cohort in regards to the patient‟s disease stage, gender or age. The incidence rates for
the combination of the markers SOX10, STAP1 and SCYL3 and a combination of all eight
markers were also included. The microarray identified fourteen (93.33%) melanoma stage 0
patients as displaying positivity for at least one markers when SOX10, STAP1 and SCYL3
were examined in combination while one (20%) of TNM stage I melanoma patient was
declared positive for the combination; however this was not significant (p=0.750).
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Table 13: Marker positivity in patients relative to stage, gender and age
Incidence
Gender

Disease Stage
Marker
SCYL3
ENO2
NRBF2
PAGE5
SOX10
STAP1
SSX7
SPANXN1
Combination of
SOX10, STAP1
and SCYL3
Combination of
all 8 markers

Stage 0
n (%)

Stage I
n (%)

13/15
(86.67%)
9/15
(60%)
7/15
(46.67%)
6/15
(40%)
4/15
(26.67%)
4/15
(26.67%)
4/15
(26.67%)
4/15
(26.67%)

4/5
(80%)
2/5
(40%)
3/5
(60%)
2/5
(40%)
2/5
(40%)
2/5
(40%)
1/5
(20%)
0/5
(0%)

14/15
(93.33%)

1/5
(20%)

15/15
(100%)

5/5
(100%)

Difference
(p-value*)

Females
n (%)

Males
n (%)

3/4
(75%)
3/4
(75%)
1/4
(25%)
2/4
(50%)
1/4
(25%)
3/4
(75%)
3/4
(75%)
0/4
(0%)

14/16
(87.5%)
8/16
(50%)
9/16
(56.25%)
6/16
(37.5%)
5/16
(31.25%)
3/16
(18.75%)
3/16
(18.75%)
4/16
(25%)

0.750

4/4
(100%)

15/16
(93.75%)

n/a

4/4
(100%)

16/16
(100%)

0.601
0.396
0.50
0.693
0.483
0.483
0.634
0.282

18-64
years
n (%)
11/13
(84.62%)
5/13
(38.46%)
7/13
(53.85%)
7/13
(53.85%)
3/13
(23.08%)
4/13
(30.77%)
4/13
(30.77%)
2/13
(15.38%)

Age
65+
years
n (%)
6/7
(85.71%)
6/7
(85.71%)
3/7
(42.86%)
1/7
(14.29%)
3/7
(42.86%)
2/7
(28.57%)
2/7
(28.57%)
2/7
(28.57%)

0.800

12/13
(92.31%)

7/7
(100%)

0.650

n/a

13/13
(100%)

7/7
(100%)

n/a

Difference
(p-value*)
0.509
0.375
0.291
0.535
0.657
0.061
0.061
0.376

*p-value obtained by Pearson chi-square and Fishers exact analysis; p<0.05 was regarded as significant
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Difference
(p-value*)
0.730
0.058
0.500
0.106
0.336
0.664
0.664
0.439

4.3 Summary of microarray data
A biomarker panel comprised of all 8 potential melanoma biomarkers would detect 20 out of
20 patient samples if a sample had to show positivity for at least one of the 8 markers;
resulting in 100% sensitivity. However, the same panel would also detect 9 out 20 control
samples under the same conditions, resulting in specificity of only 55% and therefore, the
positive and negative predictive value of a potential blood test utilising these 8 markers
combined would be 68.97% and 100% respectively (Table 14).
Table 14: Comparison of sensitivity, specificity and positive and negative predictive value
of a potential diagnostic blood test utilising the optimal panel of 5 biomarkers or a panel of
the 8 microarray identified potential melanoma biomarkers
Patients

Controls

Sensitivity

Specificity

(n =20)

(n = 20)

(%)

(%)

Positive for
at least one
of the
suggested 5
biomarker
panel

19

1

95

95

PPV = 95
NPV = 95

Positive for
at least one
of the 8
biomarkers

20

9

100

55

PPV = 68.67
NPV = 100
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Positive and
Negative
predictive
value
(%)

Table 15: Pilot study cohort reactivity against proposed 5 biomarker panel displaying 95% sensitivity and specificity (0= negative for the
marker, 1= positive for the marker)
Patient
sample
number
B17
B1
B10
B11
B12
B13
B14
B15
B16
B19
B2
B22
B24
B25
B3
B5
B6
B7
B8
B9

PAGE5

SOX10

STAP1

SSX7

SPANXN1

0
1
1
1
0
0
0
1
0
0
1
1
1
1
0
0
0
0
0
0

0
0
0
1
0
0
0
0
1
0
1
0
0
1
0
1
0
0
1
1

1
0
0
0
1
0
0
0
0
0
1
1
0
0
0
0
0
1
0
0

0
1
0
0
0
0
1
0
0
1
0
0
0
0
0
1
1
0
0
0

0
0
0
0
0
1
0
1
0
1
0
0
0
0
0
1
0
0
0
0

Control
sample
number
CC1
CC13
CC14
CC17
CC2
CC20
CC21
CC22
CC23
CC24
CC25
CC27
CC28
CC29
CC3
CC30
CC32
CC33
CC4
CC6

61

PAGE5

SOX10

STAP1

SSX7

SPANXN1

0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

By comparison, when a combination of a subset of 5 of these autoantibody markers were
analysed, they were found to provide the highest sensitivity and specificity (95%). The panel
of 5 biomarkers includes the markers PAGE5, SOX10, STAP1, SSX7 and SPANXN1. It was
found that 19 out of 20 (95%) patient samples displayed positivity for at least one of the 5
markers while only one of the control samples was positive for at least 1 (5%) of the markers
(Table 15). The positive and negative predictive value of a blood test utilising this biomarker
panel is 95% for both PPV and NPV. The difference in incidence of expression of marker
positivity between patient and control samples was established to be significant (p=0.000).
As previously shown in table 10, the mean rfu fold change values of the markers STAP1 and
SSX7 were significantly different in patient samples compared to controls (p=0.012 and
p=0.033 respectively); however, the mean rfu fold changes of the remaining three markers,
PAGE5, SOX10 and SPANXN1, contained within the subset of 5 biomarkers did not display
statistically significant differences between patient and control sera (p=0.292, p=0.063 and
p=0.543 respectively).
To graphically visualise and numerically confirm the diagnostic potential of the 8 identified
biomarkers, ROC curve analysis was performed.
Table 16: ROC curve analysis for individual markers
Biomarker name

number of
observations

ROC Area

standard error

Panel of 8 biomarkers
combined

40

0.7750

0.0695

panel of 5 biomarkers
combined

40

0.9500

0.0354

SCYL3
ENO2
NRBF2
PAGE5
SOX10
STAP1
SSX7
SPANXN1

40
40
40
40
40
40
40
40

0.7250
0.6750
0.6750
0.6750
0.6500
0.6500
0.6250
0.6000

0.0695
0.0732
0.0705
0.0615
0.0526
0.0526
0.0497
0.0459
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Table 16, and Figures 14 and 15, summarise the area under the ROC curve for each
individual marker. The standard error for each marker was also included in Table 16 to show
the deviation of the sample mean from the actual mean of the population investigated.
According to this ROC curve analysis, SCYL3 displays the highest potential to serve as a
diagnostic blood biomarker for the early detection of melanoma (area under the curve
(AUC)= 0.725) while SPANXN1 shows the lowest melanoma diagnostic biomarker potential
(AUC= 0.6). The biomarkers SSX7 and SPANXN1 represented the smallest deviation of
their sample mean to the mean of the actual population (standard error= 0.0497 and 0.0459
respectively). Figure 14 below illustrates the AUC for each individual marker as well as the
AUC of the 5 biomarker panel, denoted in the figure as „optimal markers‟ while Figure 15
compares the AUC of the 5 marker panel to a combination of all 8 microarray identified
potential diagnostic melanoma biomarkers.

Figure 14: ROC curve displaying the area under the curve (AUC) for individual markers
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Figure 15: ROC curve comparison of a diagnostic panel of 5 biomarkers and a panel of 8
biomarkers

In summary, the microarray experiment identified 8 markers as potential diagnostic
melanoma autoantibody markers with sensitivity of up to 85% and specificity of up to 100%
for individual markers, while a combination of all 8 biomarkers may yield a sensitivity of
100% and a specificity of 55%. The positive and negative predictive value of a potential
blood test utilising these 8 markers combined is 68.97% and 100% respectively while both
the positive and native predictive value are 95% for a blood test utilising the 5 marker panel.
The fold changes of rfu units showed statistically significant differences between patient and
control samples for the markers SCYL3, STAP1 and SSX7 (p=0.001, p=0.012 and p=0.033
respectively). The markers were not identified to be stage, gender or age specific, however,
these results were obtained from a small pilot study sample size (n=40) and larger sample
sizes were required to confirm the results using an enzyme-linked immunosorbent assay.

64

4.4. Final SOX10, BRDG1 (STAP1) and SCYL3 ELISA
Out of the 8 identified potential melanoma biomarkers (Figure 10 and Table 11), three
markers, namely SOX10, BRDG1 (STAP1) and SCYL3, were chosen for further
investigation utilising an enzyme-linked immunosorbent assay (ELISA). The aim was to
employ this methodology to validate the results obtained from the microarray in a larger
cohort. SOX10 and BRDG1 (STAP1) were chosen, as these markers displayed the highest
frequency in patients of those markers absent in the microarray controls study cohort (Table
11). The marker SOX10 was chosen over marker SSX7 as its association with melanoma
development had been determined previously as described in section 5.1 of this document.
There was no significant difference between patient and control samples for SOX 10
(p=0.063), whereas a significant difference was found for SSX7 (p=0.033). The lack of
significance between SOX10 samples was thought to be due to small sample size of the pilot
study (n=40), nevertheless, SOX10 was chosen for further analysis as it was readily
commercially available. SCYL3 was chosen for further study as it displayed the highest
percentage difference of frequency in patients versus controls in the microarray samples
(45%) (Table 11).
4.4.1 Final ELISA study cohort
The final study cohort (n=104) for SOX10 ELISA experiment consisted of 53 patients
recently diagnosed with melanoma and 51 healthy volunteers, confirmed as melanoma,
cancer and autoimmune disease free. The final study cohort (n=113) for BRDG1 (STAP1)
consisted of 59 patients while the final study cohort (n=114) for SCYL3 consisted of 60
patients. For both BRDG1 (STAP1) and SCYL3, the final cohort consisted of 54 controls.
The patient cohort used to assess all three markers included patients at various disease stages
(Table 17). None of the cohorts for any of the three markers included TNM stage IV
melanoma patient samples. Of the 53 patient samples in SOX10, 42 were male patients and
11 were female patients. There were 24 male and 27 female control samples. Out of the 53
patient samples for SOX10, 26 originated from TNM stage 0 in situ melanoma patients, 15
samples originated from patients with TNM stage 1 melanoma, 10 samples originated from
TNM stage II melanoma patients and 2 samples originated from TNM stage III melanoma
patients.
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Table 17: Final ELISA cohort demographical information
Gender
Marker

Disease Stage

Patient
or
Control

Male

Female

TNM 0

TNM I

TNM II

TNM III

Patient

42

11

26

15

10

2

Control

24

27

Patient

46

13

27

18

12

2

Control

26

28

Patient

46

14

27

19

12

2

Control

26

28

SOX10

BRDG1
(STAP1)

SCYL3

Of the 59 patient samples for BRDG1 (STAP1), 46 were male patients and 13 were female
patients. There were 26 male and 28 female control samples. Out of the 59 patient samples,
27 originated from TNM stage 0 in situ melanoma patients, 18 samples originated from
patients with TNM stage 1 melanoma and 12 samples originated from TNM stage II
melanoma patients and 2 originated from TNM stage III melanoma patients. Of the 60 patient
samples for SCYL3, 46 were male patients and 14 were female patients. There were 26 male
and 28 female control samples. Out of the 59 patient samples, 27 originated from TNM stage
0 in situ melanoma patients, 19 samples originated from patients with TNM stage 1
melanoma, 12 samples originated from TNM stage II melanoma patients and 2 samples
originated from TNM stage III melanoma patients. Below is a summary of the average age of
the final ELISA validation study participant for each of the three markers with respect to their
gender (Table 18). There was no significant difference in demographics between patients and
controls.
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Table 18: Average ages in years of SOX10, BRDG1 (STAP1) and SCYL3 final ELISA
cohort with respect to gender
Biomarker name

Gender

Patient (years)

Control
(years)

p-value

Male

59.55

53.73

0.587

Female

61.64

43.73

0.276

Male

60.28

52.35

0.344

Female

62

43.79

0.496

Male

60.28

52.35

0.344

Female

62.64

43.79

0.547

SOX10

BRDG1 (STAP1)

SCYL3

4.4.2 Final SOX10, BRDG1 (STAP1) and SCYL3 ELISA results. A comparison of
results where individual versus a combination of markers were used
Table 19: Mean chemiluminescence value in patients and controls for SCYL3, SOX10 and
BRDG1 (STAP1)

Marker

chemiluminescence values
in patients (mean ± Std
Dev)

chemiluminescence values
in controls (mean ± Std
Dev)

Difference
(p-value*)

SCYL3

0.199 ± 0.376

0.144 ± 0.109

0.102

SOX10

0.285 ± 0.224

0.213 ± 0.135

0.263

STAP1

0.099 ± 0.774

0.119 ± 0.091

0.074

*p-value obtained by Mann-Whitney U analysis; p<0.05 was regarded as significant
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Table 19 on the previous page summarises the final SOX10, BRDG1 (STAP1) and SCYL3
ELISA results. For each marker, the mean chemiluminescence value in samples and controls
is given.
There were no statistically significant differences in chemiluminescence values between
patients and controls in the final ELISA experiments for any of the three markers.
Table 20: Mean chemiluminescence values for SCYL3, SOX10 and SYAP1 relative to
disease stage
Marker

stage 0 value
(mean ± Std
Dev)

stage I value
(mean ± Std
Dev)

stage II value
(mean ± Std
Dev)

stage III
value (mean
± Std Dev)

Difference
(p-value*)

SCYL3

0.155 ± 0.099

0.287 ± 0.636

0.163 ± 0.123

0.123 ± 0.018

0.997

SOX10

0.268 ± 0.222

0.347 ± 0.247

0.311 ± 0.311

0.180 ± 0.079

0.525

STAP1

0.103 ± 0.089

0.093 ± 0.063

0.103 ± 0.083

0.076 ± 0.032

0.992

*p-value obtained by Kruskal-Wallis analysis; p<0.05 was regarded as significant

Table 20 shows the mean chemiluminescence values for the final ELISA patient cohort for
each of the three markers tested relative to disease stage. The ELISA confirmed that when
assessed by levels, the markers SOX10, BRDG1 (STAP1) and SCYL3, are not stage specific
in a larger cohort as there were no statistically significant differences observed in the patients
chemiluminescence values relative to disease stage.
A sample was denoted as positive for any of the three markers tested if it displayed a fold
change of 1 or more above the average of all sample chemiluminescence values and above
the overall background signal obtained across the plate/plates. A fold change of 2 or above,
utilised in the microarray experiment, was not feasible for the determination of marker
positivity on the ELISA since only 2 samples displayed a fold change above 2 and this cut-off
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was therefore determined to be too high for the ELISA data and replaced by a lower cut-off
value of 1.
Out of the final ELISA cohort, 20.75% of patient samples and only 1.96% of control samples
displayed positivity for SOX10 alone (PPV=91.66%, NPV=54.35%), thus a statistical
significance of incidence displayed between patient and control samples for SOX10
(p=0.002). For BRDG1 (STAP1), only 1.85% of all patient samples as well as 11.11% of
controls exhibited BRDG1 positivity (p=0.044, PPV=14.29%, NPV=45.28%) and 6.67% of
patient samples showed positivity for SCYL3 alone (PPV=80%, NPV=48.62%) while only
1.85% of control samples were denoted as positive for the marker (Table 21). Interestingly,
10 out of 53 (18.87%) patient samples and 7 out of 51 (19.61%) control samples were
positive for all three markers (PPV=58.82%. NPV=50.57%). Thus 50.94% of patient samples
as well as 35.29% of control samples were regarded as positive if the sample displayed
positivity for at least 1 of the three markers (PPV=85.69%, NPV=55.77%). 26 out of 53
(49.06%) patients did not however show any positivity for any of the three markers indicating
that other biomarkers need to be identified and included in a potential blood sample in order
Table 21: Frequency of positivity for SOX10, BRDG1 (STAP1) and SCYL3 in patients and
control samples
Marker

Patients

Controls

Difference (pvalue*)

SOX10 only

11/53 (20.75%)

1/51 (1.96%)

0.002

STAP1 only

1/59 (1.85%)

6/54 (11.11%)

0.044

SCYL3 only

4/60 (6.67%)

1/54 (1.85%)

0.217

combination of all
three markers

10/53 (18.87%)

7/51 (19.61%)

0.329

positive for at least
1 marker

30/53 (56.60%)

22/51 (43.14%)

0.120

Positive for none of
the markers

26/53 (49.06%)

33/51 (64.71%)

0.079

*p-value obtained by Pearson chi-square and Fishers exact analysis; p<0.05 was regarded as
significant
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to increase the sensitivity of such a diagnostic test. 33 out of 51 (64.71%) controls did not
show positivity for any of the three markers.
The following table, Table 22, summarises the sensitivity, specificity and positive and
negative predictive value of the individual three markers as well as combinations of these
markers.
Table 22: Summary of sensitivity, specificity and positive and negative predictive value of
individual markers and/ or a combination of these markers
Marker

Sensitivity

Specificity

Positive and
Negative
predictive value

SOX10 only

20.75%

98.04%

PPV= 91.66%
NPV= 54.35%

STAP1 only

1.85%

88.88%

PPV= 14.29%
NPV= 45.28%

SCYL3 only

6.67%

98.12%

PPV= 80%
NPV= 48.62%

combination of all
three markers

18.87%

86.27%

PPV= 58.82%
NPV= 50.57%

positive for at least 1
marker

56.60%

56.86%

PPV= 57.69%
NPV= 55.77%

As illustrated in Table 22, of the markers assessed by ELISA, the marker with the highest
potential for the diagnosis of melanoma patients is SOX10. According to these results, as
individual serologic biomarker SOX10 exhibits 20.75% sensitivity but up to 98.04%
specificity and a positive predictive value of 91.66% while it‟s negative predictive value is
54.35%. Following SOX10, the second best result was obtained when a combination of the
markers was used. A sensitivity of up to 56.60% was achieved when samples exhibited
positivity for at least one of the 3 markers, while it was 18.87% for samples displaying
positivity for all three markers combined in patient sera. The positive and negative predictive
value was 57.69% and 55.77% respectively for the panel where samples had to display
positivity for at least one of the three markers while the values were 58.82% and 50.57% for
the panel of a combination of all three markers.
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4.4.3 ELISA-based marker expression relative to stage, gender and age
Following the comparison of the diagnostic potential of individual autoantibody melanoma
biomarkers SOX10, BRDG1 (STAP1) and SCYL3 relative to combinations of these markers,
the data obtained from the final ELISA experiments was analysed for statistically significant
differences between patients and control marker levels and positivity with regard to TNM
disease stage, gender and age.
Further analysis was performed using the Pearson chi-square test and Fishers exact test, just
as for the microarray data, so as to examine statistical significance of microarray marker
expression in patients relative to melanoma TNM stage, gender and age (Table 23).
There was no significant difference in incidence in the pilot study patient cohort in regards to
the patient‟s disease stage, gender or age. The final ELISA experiments identified twelve
(46.15%) melanoma stage 0, ten (66.67%) melanoma stage I, 5 (50%) melanoma stage II and
zero (0%) of melanoma stage III patients as displaying positivity for at least one markers
when SOX10, STAP1 and SCYL3 were examined in combination; however, similar to the
microarray data, this was not significant (p=0.784).
Following the analysis of incidence of marker positive samples relative to disease stage,
gender and age, differences in chemiluminescence values were investigated relative to these
characteristics.
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Table 23: Marker positivity in final ELISA cohort patients relative to stage, gender and age
Incidence
Disease Stage
Marker

Stage 0
n (%)

Stage I
n (%)

Stage II
n (%)

Gender
Stage III Difference
n (%)
(p-value*)

Age

Females
n (%)

Males
n (%)

Difference
(p-value*)

18-34
years
n (%)

7/14
(50%)

12/46
(26.09%)

0.089

2/5
(40%)

SCYL3

9/27
7/19
(33.33%) (36.84%)

3/12
(25%)

0/2
(0%)

0.424

SOX10

9/26
10/15
(34.62%) (66.67%)

4/10
(40%)

0/2
(0%)

0.949

7/11
16/42
(63.64%) (38.10%)

0.119

2/5
(40%)

STAP1

8/27
4/18
4/12
(26.63%) (22.22%) (33.33%)

0/2
(0%)

0.735

5/13
11/46
(38.46%) (23.91%)

0.241

2/5
(40%)

0/2
(0%)

0.784

7/11
20/42
(63.64%) (47.62%)

0.273

2/5
(40%)

Combination
12/26
10/15
of SOX10,
STAP1 and (46.15%) (66.67%)
SCYL3

5/10
(50%)

34-64
years
n (%)

5/27
12/28
(18.52%) (42.86%)
11/25
(44%)

Difference
(p-value*)

0.239

10/23
(43.48%)

0.936

5/27
9/27
(18.52%) (33.33%)

0.636

12/25
(48%)

*p-value obtained by Pearson chi-square and Fishers exact analysis; p<0.05 was regarded as significant
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65+
years
n (%)

13/23
(56.52%)

0.438

Patient samples were grouped according to TNM stage ranging from TNM in situ to TNM
III. Interestingly, stage I melanoma patient chemiluminescence values for SOX10 were
significantly higher than control chemiluminescence values (p=0.028, Figure 16 and Table
24) while none of the other stages in SOX10 or the other two markers displayed a statistically
significant difference between chemiluminescence values. The mean and standard deviation
of SOX10 chemiluminescence values for stage 0 samples were 0.26 and 0.22, for stage I the
mean was 0.35 and the standard deviation 0.25, for stage II the mean was 0.31 and the
standard deviation 0.31, for stage III the mean was 0.18 and the standard deviation 0.08 and

Chemiluminescence reading A450

the mean of control samples was 0.21 and the standard deviation 0.13.

Figure 16: TNM stage I melanoma patients display significantly higher SOX10
chemiluminescence values than controls
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Table 24: Statistical significance for comparison of chemiluminescence values between
samples of various melanoma disease stages or between melanoma disease stages and controls

Following this, stage 0 and I samples were grouped together to represent early-stage
melanoma patients with relatively low metastatic potential and stage II and III melanoma
samples were grouped together to represent more advanced melanoma patients with higher
metastatic potential. The chemiluminescence values of both groups were analysed for
statistical differences and we found that there was no statistically significant difference
between early stage and advanced stage melanoma patient samples for any of the three
markers SOX10, BTDG1 (STAP1) and SCYL3 (p=0.588, p=0.922 and p=0.958

Chemiluminescence reading A450

Chemiluminescence reading A450

respectively.)

Figure 17: Female patients exhibit higher chemiluminescence values for SOX10 and SCYL3
than male patients
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Furthermore, analysis showed that female patients exhibited significantly higher levels of rfu
fluorescence for SOX10 than male patients (p=0.042, Figure 17) while there was no
statistically significant difference between male and female control chemiluminescence
values. Female patients also exhibited significantly higher levels of chemiluminescence for
SCYL3 than male patients while there was also no statistically significant difference between
male and female control chemiluminescence values (p=0.017, Figure 17).
To assess any age related differences between chemiluminescent values in samples, patients
were stratified into three age groups 18-34 years, 35-64 years and 65 and above (65+).
There were no statistically relevant differences in patient chemiluminescence readings for
SOX10, BRDG1 (STAP1) and SCYL3 with regard to age (p=0.710, p=0.412 and p=0.552
respectively).
4.5 Comparison of results of marker levels and incidence between microarray and
ELISA for SOX10, BRDG1 (STAP1) and SCYL3
Similarities and differences of SOX10, BRDG1 (STAP1) and SCYL3 frequency and levels
between the OGT microarray experiment and enzyme-linked immunosorbent assay were
investigated. First, the rfu values from the microarray were assessed relative to the colour
luminescence values for the pilot study cohort (Table 25). It is important to note when
comparing results that different conditions are used in different methodologies, less sample
volume on the microarray, different antibody concentrations and antigen conformations,
different development times and different readouts - fluorescence on the microarray versus
colour luminescence on the ELISAs may greatly affect the results obtained.
First, the mean and standard deviation of the fluorescence and luminosity for the same patient
cohort against the same three human recombinant proteins were compared.
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Table 25: Summary of mean, standard deviation and statistical significance of the differences
of microarray rfu vales and ELISA colour luminescence values in pilot study patient and
control samples (microarray data = pilot study testing; luminescence unit data = secondary
study results)

Marker and
Methodology

SCYL3
(microarray
rfu units)
SCYL3
(ELISA
luminescence
units)
SOX10
(microarray
rfu units)
SOX10
(ELISA
luminescence
units)
STAP1
(microarray
rfu units)
STAP1
(ELISA
luminescence
units)

Mean ±
Standard
deviation
patients

Mean ±
Standard
deviation
controls

p-value*
patients
versus
controls
(n = 40)

6188.45 ±
3991.75

3403.68 ±
1549.59

0.006

0.140 ±
0.060

0.140 ±
0.100

0.715

3521.6 ±
4234.75

2249.16 ±
1388.61

0.133

0.260 ±
0.180

0.220 ±
0.120

0.653

4852.25 ±
7845.70

2122.74 ±
1015.54

0.068

0.090 ±
0.050

0.110 ±
0.110

0.888

Mean ±
Standard
deviation
patients

Mean ±
Standard
deviation
controls

p-value*
patients
versus
controls
(n = 104
(SOX10),
113
(STAP1),
114
(SCYL3))

0.199 ±
0.376

0.144 ±
0.109

0.102

0.285 ±
0.224

0.213 ±
0.135

0.263

0.099 ±
0.774

0.119 ±
0.091

0.074

* p<0.05 was regarded as significant, statistical significance was analysed by MannWhitney U analysis
As illustrated in Table 25, only SCYL3 was found to have statistically significant differences
in levels between pilot study patient and control sample rfu values in the microarray
experiment (p=0.006). This was not evident in the ELISA results for the pilot study cohort
nor was it evident in the final study cohorts. In the ELISA experiment, none of the markers
demonstrated levels of chemiluminescence in patients that were different from controls.
However, the mean value of SOX10 colour luminescence was highest both in the pilot cohort
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as well as in the final patient cohort, while SCYL3 followed by BRDG1 (STAP1) showed
lower levels when assessed by ELISA.
Finally, both methodologies, microarray and ELISA, were compared for frequency of
positivity for SOX10, BRDG1 (STAP1) and SCYL3 and for combinations of these markers
(Table 26). Table 26 summarises the frequency of positivity of individual markers and
combinations of these markers in the pilot study and final ELISA cohort. There was a
statistically significant difference in incidence when patients were regarded positive for at
least one of these three markers in the microarray (p=0.003). This is similarly reflected in the
ELISA pilot study cohort but the statistical difference was not found to be significant
(p=0.055). Furthermore, the ELISA identified 6 out of 20 (30%) pilot study patients as being
positive for marker SOX10 alone (p=0.010) while in the extended cohort, 11 out of 53
(20.75%) patients were diagnosed as SOX10 positive only (p=0.010).
Overall, the results illustrated in Table 27 show that Microarray and ELISA results of
sensitivity and specificity as well as the positive and negative predictive values for the three
markers are highly similar. Both the microarray and ELISA results demonstrate that, using a
combination of the three markers where patients are regarded as melanoma positive when
they display positivity for at least one of the markers provides the highest sensitivity for
melanoma diagnosis (90% and 55% respectively). Both methodologies also demonstrated the
diagnostic potential of the individual marker SOX10 with high positive predictive values of
91.66% and 100% respectively.
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Table 26: Frequency of positivity for SOX10, BRDG1 (STAP1) and SCYL3 and combinations of these markers in pilot study patient and
control samples as well as final ELISA samples
Patients
(Pilot
study
ELISA
cohort)
6/20
(30%)

Controls
(Pilot
study
ELISA
cohort)
0/20
(0%)

Difference
(p-value*)

Patients
(Final
ELISA
cohort)

Controls
(Final
ELISA
cohort)

Difference
(p-value*)

0.010

11/53
(20.75%)

1/51
(1.96%)

0.002

Marker

Patients
(microarray)

Controls
(microarray)

Difference
(p-value*)

SOX10 only
n (%)

0/20
(0%)

0/20
(0%)

n/a

STAP1 only
n (%)

1/20
(5%)

0/20
(0%)

0.500

0/20
(0%)

0/20
(0%)

n/a

1/59
(1.85%)

6/54
(11.11%)

0.044

SCYL3 only
n (%)

8/20
(40%)

8/20
(40%)

0.626

0/20
(0%)

0/20
(0%)

n/a

4/60
( 6.67%)

1/54
(1.85%)

0.217

Combination
of all three
markers
n (%)

1/20
(5%)

0/20
(0%)

0.500

2/20
(10%)

2/20
(10%)

0.698

10/53
(18.87%)

7/51
(19.61%)

0.329

Positive for
at least 1
marker
n (%)

18/20
(90%)

9/20
(45%)

0.003

14/20
(70%)

8/20
(40%)

0.055

30/53
(56.60%)

22/51
(43.14%)

0.120

Positive for
none of the
markers
n (%)

2/20
(10%)

11/20
(55%)

0.003

9/20
(45%)

14/20
(70%)

0.100

26/53
(49.06%)

33/51
(64.71%)

0.079

*p-value obtained by Pearson chi-square and Fishers exact analysis; p<0.05 was regarded as significant
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Table 27: Summary of sensitivity, specificity and positive and negative predictive value of individual markers and combinations of these
markers in the pilot study cohort
Microarray
sensitivity

specificity

SOX10
(n=40)

30.00%

100.00%

STAP1
(n=40)

30.00%

100.00%

SCYL3
(n=40)

85.00%

60.00%

combination of
all 3 markers

positive for at
least 1 of the
markers

5.00%

90.00%

ELISA
positive and
negative
predictive
value

sensitivity

PPV=
91.66%
NPV=
54.35%
PPV=
14.29%
NPV=
45.28%
PPV=
80%
NPV=
48.62%

SOX10
(n=104)

43.40%

84.31%

STAP1
(n=113)

27.12%

68.52%

SCYL3
(n=114)

31.67%

75.93%

100.00%

PPV=
58.82%
NPV=
50.57%

combination of
all 3 markers

55.00%

PPV=
57.69%
NPV=
55.77%

positive for at
least 1 of the
markers
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specificity

10.00%

55.00%

positive and
negative
predictive
value
PPV=
100%
NPV=
58.82%
PPV=
0%
NPV=
50%
PPV=
0%
NPV=
50%

89.47%

PPV=
50%
NPV=
50%

73.68%

PPV=
63.64%
NPV=
66.66%

5. Discussion
Melanoma is a highly aggressive skin cancer whose progression is dramatically reduced
through early detection, followed by early surgical removal of the tumour (Balch et al.,
2011).
The overall aim of this research was to identify highly sensitive and specific serologic
autoantibody biomarkers and combinations of these markers for the early detection of
melanoma. Results from this study, although preliminary, may contribute to the development
of a diagnostic melanoma blood test which will aid the improvement of the disease
management, further increasing the number of patients diagnosed positive for the cancer at an
early stage.
We showed here that indeed melanoma early stage patients are positive for autoantibodies.
We also show that microarray technology was able to identify a panel of autoantibody
markers with high specificity and sensitivity for detection of early stage melanoma and that
this technology is superior for detection of autoantibodies in patient sera. Our results also
demonstrate that the levels of three of the identified autoantibody biomarkers may be
associated with gender but are not disease stage or age specific.
5.1 Identification of 8 autoantibody biomarkers for early stage melanoma diagnosis
utilising the OGT functional protein microarray
A major finding of this research project was the identification of 8 proteins exhibiting high
reactivity with patient sera and low or no reactivity with control sera which were therefore
considered potential diagnostic biomarkers for the early detection of melanoma patients.
The markers identified include the protein-associating with the carboxyl-terminal domain of
ezrin (SCYL3), gamma-enolase (ENO2), nuclear receptor-binding factor 2 (NRBF2), G
antigen family E member 1 (PAGE5), transcription factor SOX-10 or SRY sex-determining
region Y-box 10 (SOX10), signal-transducing adaptor protein 1 (STAP1), synovial sarcoma,
X breakpoint 7 (SSX7) and sperm protein associated with the nucleus on the X chromosome
N1 (SPANXN1).
A search of the literature confirmed an association of a number of these markers with
melanoma or the markers were hypothesised to be associated with melanomagenesis, or they
contribute to pathways and physiological changes resulting in tumour formation or
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maintenance. Some of the identified markers however, have not yet been shown to be
associated with melanoma or melanoma diagnosis and may therefore represent novel
diagnostic melanoma biomarkers.
Briefly, literature published on SCYL3, also known as PACE1, defines PACE1 as a novel
protein that interacts with the c-terminal domain of ezrin and suggests that this biomarker
may therefore play a role in cell adhesion and migration complexes in migrating cells
(Sullivan et al., 2003). The cell adhesion molecule CD44 is known to interact with the ezrin
family (ERM family) members and this CD44/ ezrin complex influences cell migration, cell
adhesion, endothelium interactions as well as tumour progression and metastasis (Martin et
al., 2003; Neisch and Fehon, 2011). Although the association of the SCYL3 protein and it‟s
autoantibodies with melanoma has not been investigated previously, its association with the
binding site ezrin suggests a relationship between elevated SCYL3 autoantibody levels and
melanoma.
ENO2 has not yet been identified as a melanoma marker. However in a recent study, gene
family member ENO1 was identified in melanoma patient sera utilising the serological
proteome approach (SERPA) (section 1.12.5). The study found ENO1 levels to be elevated in
patient sera compared to control sera and ENO1 mRNA was frequently expressed in various
melanoma cell lines (Suzuki et al., 2010).
NRBF2, also known as CORP2, is known to be one of the regulators of keratinocyte gene
expression and the literature suggests that the protein can act as a transcriptional activator
(Flores et al., 2004). However, the diagnostic relevance of anti-NRBF2 levels for the
diagnosis of melanoma is still unknown.
PAGE5, better known as cancer-testis antigen 16 (CT16), is frequently expressed in advanced
melanoma (Scanlan et al., 2002) and recent research has established PAGE5 to act as a
regulator of the expression of apoptotic and anti-apoptotic genes, thereby promoting
melanoma tumour cell survival (Nylund et al., 2012). Here we have shown for the first time
that PAGE5 may have potential in diagnosing early-stage melanoma patients.
SOX10 regulates many targets during neural crest development, including microphthalmiaassociated transcription factor (MITF), necessary for normal generation and maintenance of
melanocytes (Cronin et al., 2009; Garraway et al., 2005). High levels of SOX10 are
expressed in solid melanoma tumours (Agnarsdóttir et al., 2010; Bakos et al., 2010;
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Flammiger et al., 2008; Nonaka et al., 2008) and SOX10 ablation has been shown to arrest
the cell cycle, inducing senescence and promoting the suppression of melanomagenesis
(Cronin et al., 2013).
STAP1, also known as BRDG1, has been shown to act as a downstream target of the Tec
tyrosinase kinase positive feedback loop, increasing tyrosinase stability (Ohya et al., 1999),
thereby indirectly controlling melanin production (Hearing et al., 1992; Kobayashi et al.,
1998) which as described in section 1.1, is crucial for prevention of melanoma tumour
formation.
SSX7 was shown to be expressed in melanoma cell lines and may function as transcriptional
repressor (Güre et al., 2002), capable of eliciting cellular immune responses in cancer
patients. The SSX proteins are commonly regarded as highly useful targets for cancer
vaccine-based immunotherapy. Here we show for the first time that SSX7 autoantibody
levels may have a potential diagnostic role since patient anti-SSX7 levels were displaying
statistically significantly higher than those in control sera (p= 0.033).
SPANXN1, also referred to as cancer-testis antigen 11.6 (CT11.6), expression has been
reported in a number of tumours, including melanoma. Recent research has observed
increased SPANX gene expression in benign melanoma tumours, which was higher than the
expression in normal tissue but lower than that in metastatic melanoma tissue (Salemi et al.,
2009), indicating the validity of the detection of increased serum levels of SPANXN1
autoantibodies in early stage melanoma patient sera.
It is reasonable to believe that following apoptosis or necrosis, tumour cells release self
antigen leading to a breakdown in central tolerance resulting in the production of
autoantibodies that circulate within the patient‟s circulatory system where an extensive
supply of autoantibodies against various cancer-related antigens may be present (Chapman et
al., 2008; Lokshin et al., 2006). Patient serum samples therefore provide a precious source of
cancer antigens (Lu et al., 2008; Shoshan and Adom, 2007) which can be utilised on highthroughput platforms such as the microarray utilised in this research study to identify
melanoma related diagnostic autoantibody biomarkers.
Recent studies have shown an increase in autoantibody production in several cancers (Gnjatic
et al., 2009; Tan and Zhang, 2008) including cancer of the breast (Disis, 1994), lung
(Diesinger et al., 2002), colon (Scanlan et al., 1998), ovary (Chatterjee, 2006) prostate (Wang
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et al., 2005) and head and neck cancer (Carey, 1983), indicating a high potential of
autoantibody biomarker use for the early detection of cancer.
One example of the potential of serological autoantibodies to diagnose early-stage cancer is
the discovery of the extracellular protein kinase A (ECPKA) autoantibody as a potentially
universal cancer biomarker. In healthy mammalian cells, cAMP-dependent protein kinase A
(PKA) is an intracellular enzyme. In most cancers, this enzyme is secreted into the circulatory
system. Once secreted, the protein is known as extracellular protein kinase A (ECPKA). This
antibody was found to be elevated in a wide range of cancers at various stages of
malignancies in different cell types including bladder, breast, cervical, colon, esophageal,
gastric, liver, lung, ovarian, prostate, pancreatic, renal, small bowel, rectal, adenocystic
carcinomas, melanoma, sarcoma, thyoma, liposarcoma and leiomyosarcoma compared to
healthy controls. Blood ECPKA levels have been found to be decreased after surgical
removal of solid tumours (Kita et al., 2004). With the assumption that this excretion results in
the production of anti-ECPKA antibodies or ECPKA autoantibodies, an enzyme
immunoassay measuring the IgG of this autoantibody was developed and the sensitivity and
specificity of this biomarker for detecting the incidence of 20 different cancers was calculated
to be 90% and 87%. Anti-ECPKA autoantibody was detected in 90% of the patient samples
and in only 13% of the control samples, indicating that the presence of the ECPKA
autoantibody in sera correlates with cancer incidence (Nesterova et al., 2006). These results
are highly promising and outperform the results presented here of either the individual or
combination of melanoma markers (see table 27). However, the proposed panel of 5
identified markers results in up to 95% sensitivity and specificity (table 14). Moreover, these
markers may be melanoma specific while ECPKA is not.
5.2 The OGT functional protein microarray and in-house ELISA are appropriate
methodologies to identify and validate autoantibody biomarkers
As described in section 1.13 and 3.5, the Oxford Gene Technology (OGT) microarray
represented the optimal multiplex platform to enable melanoma autoantibody biomarker
detection due to its versatile selection of attached human recombinant proteins including
kinases, signalling proteins, transcription factors and secreted proteins which were analysed
simultaneously in one assay using only minute amounts of serum sample. The results
obtained from this assay are highly reliable as proteins were attached to the microarray glass
slide in quadruplicate with their natural and functional three-dimensional structure still intact
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and therefore conformation dependent epitopes were maintained ensuring highly-specific
binding conditions. Furthermore, the maintained three dimensional protein structures were
fully accessible for binding with autoantibodies present in patient sera as the addition of a
biotin carboxyl carrier protein tag (BCCP) to the microarray attached human recombinant
proteins or antigens resulted in the proteins being lifted up from the streptavidin-coated
microarray surface, exposing all relevant binding sites for antigen-antibody binding.
A previous study has successfully utilised the Oxford gene technology functional protein
microarray to identify autoantibodies. One study on prostate cancer, with a cohort of 73
participants, identified 15 potential autoantibody biomarkers for prostate cancer (McAndrew
et al., 2012). A combination of these biomarkers showed both a sensitivity and specificity of
greater than 90% for prostate cancer. Out of this panel, 8 of the 15 potential prostate cancer
autoantibody biomarkers had previously been associated with the cancer, indicating the
validity of this technology, and highlighted the ability of the array to identify novel
autoantibody biomarkers. By comparison, the single biomarker PSA, currently utilised in
prostate cancer screening has a sensitivity of 86% and a specificity of only 33% (Harvey et
al., 2009). The findings of this prostate cancer OGT study are currently being further
substantiated in a larger cohort of 1800 participants (McAndrew et al., 2012). We therefore
hypothesised, that the OGT array could be utilised to similarly identify autoantibodies
specific for melanoma.
When the microarray and ELISA were compared in this study for similarities in sensitivity,
specificity and positive and negative predictive value of individual markers and combinations
of three markers, the methodologies showed similar sensitivity and specificity outcomes for
single markers (apart from marker STAP1 and SCYL3) and combinations of markers. The
microarray did however display greater sensitivity.
Overall, our results indicate that the microarray is an appropriate methodology to be utilised
for the identification of autoantibody biomarkers in melanoma patient sera and that the inhouse ELISA represents an appropriate methodology to be utilised for the validation of the
identified serological autoantibody biomarkers in a larger cohort.
5.3 Increased sensitivity and specificity through utilisation of multi-biomarker panels
While ECPKA, described in section 5.1, provides significant sensitivity and specificity, to
date, no single autoantibody biomarker has been utilised as a cancer biomarker for melanoma
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specifically, presumably due to the generally low sensitivity and specificity of single markers.
Panels of multiple tumour-associated autoantibodies with high specificity and sensitivity are
sought therefore for translation into simple biomarker panel tests for routine clinical
diagnosis of early stage cancer. (Anderson and LaBaer, 2005; Caron et al., 2007;
Gunawardana and Diamandis, 2007; Huang et al., 2004; Zhang et al., 2003; Zhong et al.,
2004).
In this research, we confirmed that autoantibodies are suitable as diagnostic biomarkers for
melanoma and 8 autoantibody biomarkers displaying high reactivity with early stage
melanoma patient sera and low or no reactivity with healthy control sera were identified as
potential biomarkers. Statistical analysis of the final results showed that a combination of all
markers, where patients needed to exhibit positivity for at least one of the markers to be
denoted as melanoma positive, had the highest diagnostic potential for early stage melanoma
patients relative to healthy control samples. This was confirmed with three biomarkers by an
ELISA test. Both methodologies, the functional protein microarray and the in-house indirect
ELISA, showed similar results confirming that multiple markers are suitable for the
identification and validation of diagnostic autoantibody biomarkers for the early diagnosis of
melanoma.
The optimal autoantibody biomarker panel identified in this research study exhibits a positive
and negative predictive value of 95% which is very comparable with the positive and
negative predictive values of other potential autoantibody cancer biomarker panels currently
in commercial use and it is therefore reasonable to be considered as a potential biomarker
panel for the early diagnosis of melanoma.
The use of a combination of biomarkers for cancer diagnosis has been proven to be
favourable for the detection of various cancers.
For example, in a study by Xie et al. (2011), a new multiplex assay termed the “A+PSA”
assay (the autoantibody +PSA assay) was developed. This assay was aimed at providing a
reliable platform which will enable the diagnosis of prostate cancer patients relative to nonmalignant cases. This assay used B cell epitopes from previously defined prostate-cancerassociated antigen (PCAA), including New York oesophageal squamous cell carcinoma (NYESO-1), synovial sarcoma X breakpoint 2,4 (SSX-2,4), X antigen family member 1B
(XAGE-1b), lens epithelium-derived growth factor (LEDGF), transferrin receptor protein 9
(p90) and alpha-methylacyl-CoA racemase (AMACR). The platform allowed the
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simultaneous screening of these six autoantibodies alongside PSA and PSA screening alone
in 131 pre-surgery biopsy confirmed prostate cancer patients and 121 prostatitis and/or
benign prostatic hyperplasia patients. Xie et al. (2011) found that PSA alone had a sensitivity
of 52% and specificity of 79% in all patients while the A+PSA platforms showed a sensitivity
of 79% and a specificity of 84% in all patients. The A+PSA platform also had a decreased
false positive outcome of only 16% versus 21% when PSA alone was utilised. Overall, the
accuracy of the A+PSA test platform was as high as 81% while PSA alone only showed an
accuracy of 65% (Xie et al., 2011).
Similarly, in a breast cancer study, the SERPA approach (section 1.12.5) was utilised by
Desmetz et al. (2008)

to investigate the presence of heat shock protein 60 (HSP60)

autoantibodies in a cohort consisting of 49 ductal carcinoma in situ patients, 58 early-stage
breast cancer patients, 20 patients with other types of cancer, 20 patients with various
autoimmune diseases and 93 healthy controls. They showed that HSP60 autoantibodies are a
potential biomarker for the diagnosis of breast cancer demonstrating a sensitivity of 31.8%
while its specificity is 95.7%, resulting in an accuracy of 63.75%. A study by Chapman et al.
(2007) tested seven antigens including HER2, c-myc, p53, breast cancer type 1 susceptibility
protein (BRCA1), breast cancer type 2 susceptibility protein (BRCA2), Ny-ESO-1 and
MUC1 with a cohort of 94 healthy controls, 97 primary breast cancer sera and 40 ductal
Carcinoma in Situ (DCIS) sera. When all seven markers were used, the specificity of the
assay was found to be as high as 91-98%, even when tested for individual markers only;
however, the individual autoantigen assay sensitivity was only 3-23% in the DCIS sera and 824% in the primary breast cancer sera. By comparison, the sensitivity increased to 45% in
DCIS sera and 64% in primary cancer sera with a specificity of 85% when a combined panel
of 6 out of the 7 autoantigens were tested. Such a multimarker test could be used alongside
other cancer detection methods such as mammography, to significantly improve in breast
cancer detection.
5.4 Autoantibody biomarkers SOX10 and SCYL3 may be gender specific biomarkers
but SOX10, BRDG1 (STAP1) and SCYL3 are not melanoma disease stage or age
specific
When microarray identified markers, including SOX10, BRDG1 (STAP1) and SCYL3 were
analysed to examine statistical significance of the microarray pilot study cohort marker
expression relative to melanoma TNM stage, age and gender incidence, no statistically
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significance was found which would indicate a lack of association of autoantibody levels and
therefore marker expression with any of the above mentioned criteria. The lack of significant
statistical difference between patient sample stages may indicate that autoantibody levels are
not indicative of tumour burden. Autoantibodies may be formed early in the disease in
response to abnormal proteins but are not produced at increasing levels at increasing disease
stages.
When chemiluminescence values of the final ELISA cohort were compared for each marker,
we found that female patient autoantibody chemiluminescence levels were significantly
higher than those of male patients in the final SOX10 and SCYL3 ELISA (p=0.042 and
p=0.017 respectively). This finding has not been shown previously in other cancers.
It is interesting to note that the number of female and male patient samples was independent
of the primary researchers and therefore the number of female and male patient samples
received mirrors the number of female and male patients being diagnosed over the course of
the study. There were only 4 female patient samples and 16 male patient samples in the
microarray study resulting in a 4:1 ratio of males being diagnosed with melanoma in
comparison to female patients. In the final ELISA cohort, there were up to 46 male patient
samples and 14 female patient samples, resulting in a 4.18:1 ratio of males being diagnosed
with melanoma in comparison to females. This finding coincides with increased melanoma
risk associated with males (Green et al., 2012), but fails to explain the higher association of
these markers with female patients. Further research in a larger cohort is required to confirm
these results.
5.5 The importance of a diagnostic blood test for melanoma

Currently, clinicians may diagnose melanoma initially through the visual examination of
suspicious moles using the ABCDE rule, which confirms a lesion as melanoma positive if it
exhibits an asymmetrical shape, irregular border, colour variability of the pigmentation of the
skin and if the moles diameter has advanced past 6mm, indicating that the mole is evolving
by displaying further symptoms such as itching, bleeding or crusting (Abbasi et al., 2004;
Rigel et al., 2005). Although highly utilised, the changes observed in this rule are not highly
specific to melanoma and less than 17% of all benign naevi displaying the tendency to show
such changes are actually melanomas (Goulart et al., 2011). Further limitations of the
ABCDE rule utilisation for the early detection of melanoma include the high likelihood of
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negligence of smaller lesions through the employment of the 6mm diameter cut-off and these
lesions may remain untreated (Helsing and Loeb, 2004; Rhodes, 2006).

Another rule,

denoted as the consumer-friendly rule to assess lesions for asymmetry and colour for
melanoma suspicious lesions (AC rule) showed that 91% of the general population observed
in a study, correctly diagnosed themselves as melanoma burdened while when used by
dermatologists, the sensitivity of the test was 88%. The specificity of this melanoma
diagnosis rule however was only 64% in the general population and 88% when utilised by
dermatologists to diagnose their patients (Luttrell et al., 2011). Most skin cancers, including
melanoma, are detected by skin self-examination (SSE) (Hamidi et al., 2008), with SSE
sensitivity values ranging from 25% to 93% and specificity values ranging from 83% to 97%
(Hamidi et al., 2010). In fact, in Australia, 44% of all melanomas (McPherson et al., 2006)
and 73% of melanoma recurrences are detected by the patient or the patient‟s partner
(Francken et al., 2007). Studies have also found that melanoma lesions detected by SSE are
generally thinner, indicating an earlier disease stage which may greatly influence the patient‟s
survival rate (Hamidi et al., 2008; Janda et al., 2011). However, lesions on hard-to-see body
sites are often missed in skin self-examinations (Youl et al., 2011) which do not tend to be
thorough (Weinstock et al., 2007). The success of SSE may further be compromised
depending on personal factors such as the patients skin cancer knowledge, personal history
and therefore higher perceived risk of skin cancer, previous conversation with a provider
about sun protection, and SSE self-efficiency (Hamidi et al., 2008). On the other hand,
clinical skin examination (CSE) was found to lead to earlier detection of skin cancer in
general (Carli et al., 2003a) and melanoma thickness levels were found to be further
decreased when compared to SSE diagnosis (Carli et al., 2003b; Hamidi et al., 2008) which
ultimately led to a substantial favourable impact of CSE on melanoma mortality (Katalinic et
al., 2012). There are two types of dermoscopes, utilised to aid CSE, which can detect various
features of the melanoma lesion such as seborrheic keratosis (Wurm et al., 2010), vascular
structures and shiny white streaks which may indicate fibrosis (Benvenuto-Andrade et al.,
2007). Although dermoscopy may be regarded as the golden standard for melanoma detection
(Wurm et al., 2010), it still displays a limited scope of observable structures (HoffmannWellenhof et al., 2009) and requires a conceptual level of knowledge and experience to
distinguish melanoma features and patterns from those of normal naevi (Rosendahl et al.,
2011) as well as adding several minutes to the clinical visit (Zalaudek et al., 2008).
Reflectance confocal microscopy (RCM), which uses a near infrared laser beam to penetrate
the upper layers of the skin to allow definition of cellular structures and morphology of the
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epidermis, dermoepidermal junction and dermis (Hoffmann-Wellenhof et al., 2009), and total
body photography (TBP), which is used to document multiple lesions covering the body over
time and observe changes in the lesions (Wurm et al., 2010), may also be utilised to diagnose
melanoma. Both technologies are non-invasive and exhibit high sensitivity and specificity
scores (Ferris and Harris, 2012; Wurm et al., 2010), but large-scale trials are still required to
determine their actual usefulness in melanoma detection (Hoffmann-Wellenhof et al., 2009;
Wurm et al., 2010) and both diagnostic methods furthermore elongate the time required per
patient for each clinical visit.
Finally, once a biopsy has been obtained from a patient for further analysis, the collected
tissue sample is analysed by cytological analysis and immunohistochemistry, using markers
such as Human Melanoma Black 45 (HMB45), S100 calcium binding protein B (S100B) and
Protein melan-A (MLANA) also known as melanoma antigen recognised by T-cells 1
(MART-1); to assess the presence of cutaneous melanoma and therefore diagnose the patient
from which the tissue originated (Mocellin et al., 2008; Pflugfelder et al., 2013). In order to
increase the accuracy of these analytical tests, it is necessary to utilise a larger number of
markers with high sensitivity and specificity for cutaneous melanoma. In cases where
immunohistochemistry results are indecisive, electron microscopy may be utilised (Lai et al.,
1998). On occasion however, there may be difficulty in diagnosing melanoma as the
phenotype and genetic makeup can resemble the cells of other cancer types (Sheffield et al.,
2002).
Therefore, currently utilised techniques for the early stage diagnosis of melanoma, exhibit
many advantages but also several disadvantages. Some of the disadvantages resulting from
incorrect melanoma diagnosis for example through limitations in the diagnostic tests and
technologies listed above, include the corresponding results of melanoma misdiagnosis such
as the psychological impact on a healthy individual of a possible melanoma diagnosis, an
increased number of unnecessary surgical procedures on benign lesions along with their
accompanying costs and possible delays of diagnosis confirmation (Carli et al., 2004;
MacKie et al., 2003). Resent focus has therefore been gathering momentum in search for
biomarkers which may be used in a diagnostic melanoma blood test as an alternative
diagnostic technique.
A diagnostic blood test which incorporates the autoantibody biomarkers identified in this
research study, by using a functional protein microarray and validated in a larger cohort using
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an indirect enzyme-linked immunosorbent assay (ELISA), may be used as a second
independent test for melanoma positivity, counteracting the limitations mentioned above and
providing improved and accurate melanoma diagnosis. The blood test will be less invasive
than the collection of a biopsy tissue sample; it will only cause minor discomfort to the
patient and can be readily performed by any trained phlebotomist employed at the appropriate
clinical institution, centre or hospital. The cost of the blood test may be less extensive than
unnecessary surgical skin excisions and will add less time to each clinical visit than other
diagnostic methods currently in use. It is anticipated that this blood test may be used in
conjunction with the currently utilised diagnostic techniques.
To date, serological biomarkers are generally not utilised to diagnose melanoma, but may
prove valuable, particularly in occult melanoma cases where the primary tumour is not found
and therefore none of the above mentioned techniques are applicable (Kamposioras et al.,
2011). A diagnostic blood test also be useful for the diagnosis or monitoring of patients with
mole counts greater than 100 across their body surface, which often pose a problem as the
visual monitoring of these lesions is very time consuming and therefore clinicians may have
difficulty in monitoring the patient‟s skin lesion changes. The blood test will not suffer from
detection bias as may be the case for other diagnostic techniques and could eliminate the
potential of negligence of suspicious lesions located on hard-to-see body sites.
Currently, following the surgical excision of their primary tumour, melanoma patients
generally do not receive further treatment and PET/ CT scans are currently the only way to
monitor a limited number of patients with suspected advanced melanoma (Marsden et al.,
2010). Therefore, a blood test may not only be used to diagnose melanoma patients but also
to monitor their disease status.
5.6 Limitations of the study
The sample size of the pilot study cohort utilised in the microarray experiment to identify the
panel of 8 diagnostic early stage melanoma biomarkers was relatively small (n=40) and
therefore these markers may not be optimal for melanoma. An increased sample size may
produce statistical significance in areas of this research that were otherwise lacking in
significance. Furthermore, although the microarray utilised in this research study consisted of
1627 human recombinant proteins derived from various tumours there may have been
markers present in high levels in patient sera and absent or present in very low levels in
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control sera that may have been missed in our investigation simply because they were not
part of the microarray.
For the ELISA experiments, research was restricted to commercially available human
recombinant proteins and these may have differed slightly from those on the microarray. It is
also important to note that the ELISA methodology did not incorporate a BCCP tag as used in
the microarray experiment and therefore, the three dimensional structure of the proteins used
in the ELISA experiments were not lifted away from the ELISA plate surface which may
have resulted in important autoantibody binding epitopes being inaccessible to autoantibody
binding. Furthermore, although healthy participants of the study were asked if, to the best of
their knowledge, they have ever been diagnosed with any cancer or autoimmune disease, they
may have been undiagnosed for any of these conditions and may therefore not accurately
represent a true control sample to which melanoma patient samples should be compared.
Furthermore, the different conditions utilised in both the microarray and ELISA experiments
limit the levels of comparison between the two methodologies.
5.7 Suggested future experiments
Since a combination of the markers, SOX10, BRDG1 (STAP1) and SCYL3, and levels of the
single marker SOX10 showed high potential to serve as diagnostic autoantibody biomarkers
for the early detection of melanoma, follow up studies with increased sample sizes should be
conducted. As mentioned in the results section of this document, a panel comprising the
markers PAGE5, SOX10, STAP1, SSX7 and SPANXN1 may provide up to 95% sensitivity
and specificity to diagnose melanoma and therefore, this panel is suggested to be investigated
further in future studies. These studies should also include a larger sample size of more
advanced stages of melanoma in order to determine if the identified markers display only
diagnostic or also prognostic biomarker potential. It would further be advised to test the
individual markers as well as combinations of these markers against a variety of samples
from patients with non-melanoma cancers to identify whether these markers are melanoma
specific and since the levels of autoantibodies in patients with autoimmune diseases may
greatly affect potential cancer-related diagnostic autoantibody levels, future studies should
also test samples from patients with various autoimmune diseases for the markers identified
as melanoma markers, to ensure that the markers are indeed truly specific. Furthermore,
screening an increased sample cohort on the microarray may result in the identification of
other, potentially novel diagnostic autoantibody biomarkers for the early detection of
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melanoma patients. Finally, any research performed in this topic area has the potential to add
to the current knowledge on melanoma formation and progression and may therefore provide
future targets for therapeutic interventions.
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6. Conclusion
In conclusion, melanoma is a highly aggressive skin cancer, the progression of which is
dramatically reduced by early detection, followed by early treatment (Balch et al., 2011). We
hypothesised that increased levels of autoantibodies in the serum of early stage melanoma
patients are indicative of a positive disease status and therefore may be utilised to assist with
diagnosis of melanoma at an early stage. Recent studies have shown an increase in
autoantibody production in several cancers (Gnjatic et al., 2009; Tan and Zhang, 2008)
including cancer of the breast (Disis, 1994), lung (Diesinger et al., 2002), colon (Scanlan et
al., 1998), ovary (Chatterjee, 2006) prostate (Wang et al., 2005) and head and neck cancer
(Carey, 1983), indicating a high potential of autoantibody biomarker use for the early
detection of cancer.
Here we have identified a panel of 8 potential diagnostic biomarkers for the early detection of
melanoma through the utilisation of the OGT functional protein microarray. We have further
validated the microarray results of 3 of the identified markers in a larger cohort by
performing an enzyme-linked immunosorbent assay (ELISA) and found that a panel
comprised of the markers SOX10, BRDG1 (STAP1) and SCYL3, where a sample had to
display positivity for at least one of the markers in order to be regarded as melanoma
positive, displayed the highest diagnostic potential for early stage melanoma patients. The
single marker, SOX10, also displayed high diagnostic potential. Furthermore we have
confirmed that the microarray and ELISA are appropriate methodologies for the
identification and validation of autoantibody biomarkers as their final sensitivity and
specificity scores obtained for single markers and combinations of these markers are highly
similar. Finally, we found that the markers SOX10 and SCYL3 may be gender specific as
female patients showed significantly higher autoantibody levels of these markers than male
patients. We did not find any patient age or disease stage associations with these markers.
The major limitation of the study was the small pilot study sample size and different
experimental conditions utilised in the two methodologies compared. It is suggested that
further studies on the identified melanoma biomarkers should be performed to validate the
results obtained from this study in an increased sample cohort of early stage melanoma
patients and patients of other cancers as well as autoimmune diseases to validate these
findings. Ultimately, the detection of a panel of autoantibodies may be utilised for the
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development of a routine diagnostic tool, such as a blood test, to aid in the early detection of
melanoma.
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PARTICIPANT I NFORMATION

S HEET

Development of a blood test for Cutaneous Melanoma
A/Prof Mel Ziman, Mr. Mark Lee, A. Prof. Robert Pearce, Dr. Lister, Dr. Chan, Dr. Amanda
Ireland, Ms. Anna Reid, Mr. James Freeman, Ms. Dr Johan Poole-Johnson, Dr. John Anson,
Dr. Will Colon, Dr. Arif Anwar, Ms. Hasmawati Yahaya, Ms. Pauline Zaenker
Please take time to read the following information carefully and discuss it with your friends,
family and general practitioner if you wish. Ask any question if some part of the information
is not clear to you or if you would like more information. Please do this before you sign this
consent form.
Who is funding this study?
Edith Cowan University - in the form of a research grant, the Office of Research and
Innovation strategic fund.

Contact persons:
Should you have questions about the study you may contact:
A/Prof. Mel Ziman

Phone No.

6304 3640 Mobile: 041992985

All study participants will be provided with a copy of the Information Sheet for their personal
records.
1. You may decide to be in the study or not take part at all. If you do decide to take part in this
study, you may stop at any time. However, before you decide, it is important that you
understand why this research is being done and what it will involve.
2. You may wish to have a member of your family or a friend with you while you are told about the
study. You may ask questions and all questions will be answered to your satisfaction.

Whatever your decision, this decision will not lead to any penalty or affect your regular
medical care or any benefit to which you are otherwise entitled.
The following information sheet will explain the study and will include details such as:
o Why this trial might be suitable for you;
o The possible risks (side-effects) and benefits of the new test;
o The type, frequency and risks of any medical tests or procedures required by the
trial;
o The nature of your participation including how many visits you will make to the
hospital
o Your rights and responsibilities
o Who is funding this study
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What is the purpose of the study?
This study is a research project in which we are investigating serum levels of
autoantibodies in the peripheral blood of patients with cutaneous melanoma relative
to autoantibody serum levels in healthy individuals. It is anticipated that these
autoantibodies may be used as markers to diagnose melanoma in an early-stage to
improve patient survival rates.
Why is this study suitable to me?
You have been invited to participate in this study because you have been diagnosed
with cutaneous melanoma, or you have been asked to participate as a normal
healthy volunteer.
How long will I be in this study?
If you agree to participate you will be asked to undergo a skin examination by a
practicing clinician (either a dermatologist or a plastic surgeon). This service will be
provided as part of your routine examination by your clinician or will be provided free
of charge if you are a healthy volunteer. You will then be asked to provide a blood
sample.
If you agree to participate as a patient you will be asked to provide blood samples at
the time of surgical removal of your tumour.

What will happen if I decide to be in this study?
The study will be conducted over a two year period. If you are a healthy volunteer
you will be asked to undergo a free skin examination and provide one blood sample
at a time that is suitable for you.
 If you are a patient with cutaneous melanoma you are required to provide a small
blood sample at the time of diagnosis and you may be required to give a blood
sample once again over the course of two years.
 The amount of blood required for this study is small (only 9ml). Blood will be
drawn into serum separation blood tubes.
 Generally you will not be contacted between visits. If you require general
information about the research at any time then you are able to contact the
researchers should you wish to do so.
 Your blood will be tested relative to blood from other participants and those of
healthy volunteers. Because your sample is only identifiable by a coded number,
the researchers performing the tests will not know which sample is yours.
 Samples will be stored in the locked freezers during the melanoma research
study conducted at Edith Cowan University or at Oxford Research Laboratories
and will then be discarded upon completion of the study or upon your written
request.
Are there any reasons I should not be in this study?:
The clinical staff collaborating in this study will discuss these with you in detail and
will ensure that this trial is both safe and appropriate for you.
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What are the costs to me?
There will be no additional costs over and above your visits to the doctor. Blood will
be taken at the hospital or clinic when and where you visit your doctor for treatment
and follow up visits.
What are the possible benefits of taking part?
The results of these studies may be of interest to you and your family and you may
decide whether or not the information may be disclosed to your family.
However, the research will not at this stage provide you with any detailed information
about your general health or genetic diseases now or in the future.
Donation of your sample may assist researchers to provide a more detailed and
specific diagnosis of melanoma in the future. The results from the study may be
used to commercialise a blood test for melanoma to ensure the provision of this
technology for all patients in the future.
How will my safety be ensured?
In this study, the sample that you provide is a blood sample and there is very little
risk to you in this procedure as only a small volume of blood is required for the test.
However please do not hesitate to contact the study coordinator or your doctor in
relation to any adverse effects you think you are experiencing. If the effects are
severe enough, the doctor may stop your participation in the study.
The study may produce abnormal results in which case you and your clinician will be
notified and additional clinical tests will be performed if your doctor feels it is in your
best medical interest. When you stop participation in the study you will be
reassessed as you were at the beginning of the study as a patient.
What alternatives do I have to going on this study?
This study does not affect your treatment. Your treatment will continue in the same
manner whether you decide to participate in the study or not.
You may wish to discuss with your doctor or the researchers how the test will benefit
patient treatment in the future even though there may be no immediate benefit to
your own treatment if you participate in the study.
What are the possible side effects, risks and discomforts of taking part?
In this study, only a small volume of blood is taken (9ml) so there is very little risk to
you in this procedure. You may suffer a small amount of discomfort when you donate
the blood sample, like the feeling of a pin prick.
The likelihood of side effects from donating blood are small, around 1 in 100.
However should you suffer any side effects please tell your doctor immediately about
any new or unusual symptoms that you get.
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What if new information comes along during the study?
Sometimes new information about a blood test becomes available as a study
progresses. You will be told about any information that could be important to you and
to your decision to continue in the study. If you then want to continue in the trial, you
may be asked to sign a revised consent form.
Stopping the study early:
Sometimes a trial needs to be stopped early because of safety concerns, because
the trial is not effective enough, because the trial has been completed or for other
reasons. If this occurs, the reasons will be explained to you and your treatment will
continue as it would have without the test. Your treatment will not be influenced by
the test in any way.
What happens at the end of the study?
At the end of the study your visits to your doctor will continue and your treatment will
not be affected by the outcome of the research.
What if something goes wrong?
You will receive the best medical care available during and after the test, but
because these are still relatively new tests, unexpected results may be obtained. In
the unlikely event of risks to your health being identified then you will be provided
with the necessary care.
Medical treatment will be provided at no cost to you for research-related harm. The
term “research-related harm” means both physical and mental injury caused by the
product or procedures required by the trial.
Your participation in this study does not prejudice any right to compensation which
you may have under statute or common law.
Will my taking part in this study be kept confidential?
The researchers will need to collect personal data about you, which may be
sensitive, such as your relevant health information. The researchers may also need
to get some of your health information from other health service providers, eg
another hospital, pathology laboratory, radiographer, GP or other medical specialist.
Any personal or health information will be kept private and confidential. It will be
stored securely and only authorised persons, who understand it must be kept
confidential, will have access to it. Your study details will be given a number so that
your identity will not be apparent. The trial records will be kept at The School of
Medical Sciences at Edith Cowan University (ECU) during the study and in a locked
archive for at least 5 years from the time the study is closed, and may be destroyed
at any time thereafter.
Authorised representatives of the researchers, the investigating doctors, the Hospital
or University Human Research Ethics Committees, Research Governance and other
regulatory bodies may require access to your study records to verify study
procedures and/or data. Some of your information may be sent to people in other
countries for these purposes. In all cases when dealing with your information, these
people are required to comply with privacy laws that protect you.
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Your sample and general information about your health (no personal data) may be
sent to people at other laboratories in Australia or overseas. Researchers in other
laboratories will not be able to identify you as only the principle researchers at ECU
will have access to your personal information and this will be kept in locked filing
cabinets and on password protected computer disks.
The result of the research will be made available to other doctors through medical
journals or meetings, but you will not be identifiable in these communications. By
taking part in this study you agree not to restrict the use of any data even if you
withdraw. Your rights under any applicable data protection laws are not affected.
Will I find out the results of the study?
The value of the research is not known at this time. You will be notified of the results
of the research at your request and the outcomes of the research as a whole may be
provided to you upon completion of the project.
Who has reviewed the study?
The Edith Cowan University Human Research Ethics Committee have reviewed this
study and have given their approval for the conduct of this research trial. In doing so
this study conforms to the principles set out by the National Statement on Ethical
Conduct in Research involving Humans and according to the Good Clinical Practice
Guidelines.
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CONSENT FORM
Development of a Blood Test for Cutaneous Malignant
Melanoma
All study participants will be provided with a copy of the Information Sheet for
their personal records.

Investigators: A/Prof Mel Ziman, Ms. Pauline Zaenker, Mr. Mark Lee, A. Prof. Robert
Pearce, Dr. Lister, Dr. Chan, Ms. Anna Reid, Ms. Dr Johan Poole-Johnson, Dr. Arif Anwar

Participant Name:_________________________________________

Date of Birth: _______________

1. I have been given clear information (verbal and written) about this study and have
been given time to consider whether I want to take part.
2. I have been told about the possible advantages and risks of taking part in the study
and I understand what I am being asked to do.
3. I have been able to have a member of my family or a friend with me while I was told
about the study. I have been able to ask questions and all questions have been
answered satisfactorily.
4. I know that I do not have to take part in the study and that I can withdraw at any
time during the study without affecting my future medical care. My participation in
the study does not affect any right to compensation, which I may have under statute
or common law.
5. I agree to take part in this research study and for the data obtained to be published
provided my name or other identifying information is not used.
6. I provide consent for my medical history to be made available to the researchers.
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7. I understand that the outcome of the study may be used to commercialise a blood
test for melanoma and that my sample may be sent overseas for analysis to assist
with this process.
8. I understand that my sample and associated data may be used for future melanoma
research but only for melanoma research conducted by researchers at Edith Cowan
University.
If you are unclear about anything you have read in the Participant Information Sheet or
this Consent Form, please speak to your doctor or contact the researchers before signing
this Consent Form.

Name of Participant

Signature of Participant

Date

Name of Investigator

Signature of Investigator

Date

125

8.4 Pilot study cohort data
Patients:
TNM
Breslow
Gender disease
thickness
(M/F)
stage at
(mm)
diagnosis
not
M
0
reported
not
M
0
reported

Patient
sample
number

Age
(yrs)

B1

48

B2

76

B3

66

M

0

0.5mm

B5

65

M

0

B6

63

M

B7

36

B8

Clark´s
level
not
reported
not
reported

Malignancy Ulceration
(Yes/ No)
(Yes/ No)
No

No

not reported

not
reported

3

No

No

not
reported

not
reported

No

Yes

0

insitu

1

not reported

No

M

1

0.3mm

1

not reported

Yes

75

M

0

insitu

not reported

No

B9

26

M

0

insitu

not reported

56

M

0

not
reported

not
reported

B10

not
reported
not
reported
not
reported

No

No

B11

57

F

I

0.35mm

2

none

none

B12

45

F

0

not
reported

No

No

B13

71

M

0

not
reported
not
reported

1

No

No

B14

73

M

I

0.2mm

not
reported

No

Yes

B15

63

M

0

insitu

TBA

No

No

B16

56

M

I

1.0mm

4

No

No

B 17

66

F

0

insitu

No

No

B19

62

M

0

1.5mm

No

No

B22

51

M

0

na

No

No

B24

46

M

0

0.28mm

No

Yes

B25

57

F

I

0.38mm

No

Yes
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not
reported
not
reported
not
reported
not
reported
3

Controls:
Control
sample
number
CC1
(A-J)
CC2
(A-J)
CC3
(A-J)
CC4
(A-J)
CC6
(A-J)
CC13
(A-J)
CC14
(A-J)
CC17
(A-J)
CC20
(A-J)
CC21
(A-J)
CC22
(A-J)
CC23
(A-J)
CC24
(A-J)
CC25
(A-J)
CC27
(A-J)
CC28
(A-J)
CC29
(A-J)
CC30
(A-J)
CC32
(A-J)
CC33
(A-J)

Age
(yrs)

Sex
(M/F)

55

F

60

F

43

F

60

M

25

M

47

M

50

M

53

M

49

M

60

M

37

M

58

F

67

M

75

M

68

M

50

M

59

M

65

M

80

M

49

M
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8.5 Microarray data and statistical analysis

The following tables show the samples positive for the 8 potential biomarkers identified on
the OGT microarray. The sample number, participant age, gender and rfu fold change for the
appropriate marker is included below as well as the mean and data range of each marker:
SCYL3:

Sample and TNM
stage
TNM stage
0
TNM stage
I
control
B1
B10
B11
B12
B13
B14
B15
B16
B19
B2
B22
B25
B3
B5
B6
B8
B9
CC13
CC17
CC2
CC20
CC22
CC24
CC29
CC4

Age
(years)

Gender
(M =
male, F
=
female)

48
56
57
45
71
73
63
56
62
76
51
57
66
65
63
75
26
47
53
60
49
37
67
59
60

M
M
F
F
M
M
M
M
M
M
M
F
M
M
M
M
M
M
M
F
M
M
M
M
M
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Fold
change mean and
values
data
for
range
SCYL3
2.1
5
2.3
3.7
2.4
4.2
2.7
3.3
6.2
3.7
3.9
2.3
4.9
7.5
7.9
3
2.6
3.1
2.4
4.8
2
3.4
2.2
4.3
2.1

3.98
(2.1-7.9)

3.04
(2-4.8)

ENO2:

Sample and TNM
stage
TNM stage 0
TNM stage I
control
B17
B12
B13
B15
B19
B2
B25
B3
B5
B7
B8
CC13
CC17
CC22
CC24

Age
(years)

Gender
(M =
male, F
=
female)

Fold
change
values
for
ENO2

66
45
71
63
62
76
57
66
65
36
75
47
53
37
67

F
F
M
M
M
M
F
M
M
M
M
M
M
M
M

2.2
8.4
4.6
2.7
2.4
2.2
3.5
2.3
10.9
2.4
3.2
4.4
2.4
2.4
2.9

Age
(years)

Gender
(M =
male, F
=
female)

Fold
change
values
for
NRBF2

mean and
data
range

4.07
(2.2-10.9)

3.03
(2.2-4.4)

NRBF2:
Sample and TNM
stage
TNM stage 0
TNM stage I
control
B10
B14
B15
B22
B24
B25
B3
B5
B6
B7
CC13
CC20
CC3

56
73
63
51
46
57
66
65
63
36
47
49 129
43

M
M
M
M
M
F
M
M
M
M
M
M
F

2.1
4.5
3.2
2.6
4.6
2.2
10.3
5.8
2.4
6.2
3.6
5.9
10.6

mean and
data
range

4.39
(2.1-10.3)

6.70
(3.6-10.6)

PAGE5:
Sample and TNM
stage
TNM stage 0
TNM stage I
control
B1
B10
B11
B15
B2
B22
B24
B25
CC26

Age
(years)

Gender
(M =
male, F
=
female)

Fold
change
mean
values and data
for
range
PAGE5

48
56
57
63
76
51
46
57
59

M
M
F
M
M
M
M
F
M

6.6
2
2.4
2.6
7.8
2.7
2.8
2.1
3.2

Age
(years)

Gender
(M =
male, F
=
female)

Fold
change
values
for
SOX10

mean
and data
range

57
56
76
65
75
26

F
M
M
M
M
M

2.4
3.9
3.5
2.2
2
3.4

2.90
(2-3.9)

3.63
(2-7.8)

3.2

SOX10:
Sample and TNM
stage
TNM stage 0
TNM stage I
control
B11
B16
B2
B5
B8
B9
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STAP1 (BRDG1):
Sample and TNM
stage
TNM stage 0
TNM stage I
control
B17
B12
B2
B22
B25
B7

Age
(years)

Gender
(M =
male, F
=
female)

Fold
change
values
for
STAP1

mean
and data
range

66
45
76
51
57
36

F
F
M
M
F
M

12
3.4
7.2
2.2
2
3.2

5.00
(2-7.2)

Age
(years)

Gender
(M =
male, F
=
female)

Fold
change
values
for
STAP1

mean
and data
range

66
45
76
51
57
36

F
F
M
M
F
M

12
3.4
7.2
2.2
2
3.2

5.00
(2-12)

SSX7:
Sample and TNM
stage
TNM stage 0
TNM stage I
control
B17
B12
B2
B22
B25
B7
SPANXN1:
Sample and TNM
stage
TNM stage 0
TNM stage I
control
B13
B15
B19
B5

Age
(years)

Gender
(M =
male, F
=
female)

Fold
change
values for
SPANXN1

mean
and
data
range

71
63
62
65

M
M
M
M

2.7
2
2.7
4

2.85
(2-4)
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